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Abstract
The adenovirus (Ad) vector is an attractive candidate for vaccines designed to elicit cellular immunity as
studies in animals and humans have proven Ad vectors are capable of inducing large transgene-specific T-cell
responses. However, given that natural infection by Ad is prevalent globally, pre-existing Ad immunity is a
major impediment to the use of recombinant Ad-based vaccines. Though the prevalence of pre-existing
neutralizing antibodies has been well characterized, there is a lack of information on the functionality and
phenotype of Ad-specific T-cell responses among heterogeneous human cohorts. The lack of protection and
possible increased risk of HIV infection in the Merck Ad5 HIV vaccine STEP trial further highlights the need
to understand vector-specific immunity in order to produce safe, effective Ad-based vaccines. We aimed to
characterize Ad-specific T-cell responses in humans following natural infection and vaccination. Ad-specific T-
cell responses were measured by stimulating peripheral blood mononuclear cells (PBMCs) with whole Ad
vector or overlapping Ad hexon peptide pools. PBMCs were obtained from 17 healthy adults to study natural
infection and longitudinally from 40 participants in Merck phase I Ad5 HIV vaccine studies, 10 of which were
enrolled in the STEP trial precursor study using the same vector, dosing, and schedule used for the STEP
study. T-cell phenotype and functionality were measured by polychromatic flow cytometry. We found that
both CD4+ and CD8+ Ad5-specific T-cells were universally present in subjects independent of their
serostatus. Ad5-specific CD8+ T-cells exhibited an effector phenotype and produced the effector functions
MIP1α and perforin whereas Ad5-specific CD4+ T-cells had an effector memory phenotype producing IL-2,
IFN-γ and TNFα. Ad5-specific T-cells recognized both conserved and variable hexon epitopes making them
highly cross-reactive with chimpanzee serotypes. Upon Ad5-based vaccination, Ad5-specific CD4+ T-cells
were only transiently expanded and there were no differences in activation or mucosal homing marker
expression between Ad5-seronegative and Ad5-seropositive subjects. These data suggest the increased risk of
HIV infection observed in the STEP trial was not a result of Ad5-specific CD4+ T-cells. Ad5-specific CD8+
T-cells were also transiently expanded by Ad5-based vaccination, however, there were no changes in
functionality. Together, these data suggest though pre-existing Ad-specific T-cells may reduce vaccine efficacy,
they should not represent a safety concern for the use of Ad-based vaccines.
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ABSTRACT  
  
ADENOVIRUS SPECIFIC T-CELL RESPONSES IN HUMANS 
FOLLOWING NATURAL INFECTION AND VACCINATION 
 
Natalie A. Hutnick 
Michael R. Betts 
  
The adenovirus (Ad) vector is an attractive candidate for vaccines 
designed to elicit cellular immunity as studies in animals and humans have 
proven Ad vectors are capable of inducing large transgene-specific  
T-cell responses. However, given that natural infection by Ad is prevalent 
globally, pre-existing Ad immunity is a major impediment to the use of 
recombinant Ad-based vaccines. Though the prevalence of pre-existing 
neutralizing antibodies has been well characterized, there is a lack of 
information on the functionality and phenotype of Ad-specific T-cell responses 
among heterogeneous human cohorts. The lack of protection and possible 
increased risk of HIV infection in the Merck Ad5 HIV vaccine STEP trial 
further highlights the need to understand vector-specific immunity in order to 
produce safe, effective Ad-based vaccines. We aimed to characterize Ad-
specific T-cell responses in humans following natural infection and 
vaccination. Ad-specific T-cell responses were measured by stimulating 
peripheral blood mononuclear cells (PBMCs) with whole Ad vector or 
overlapping Ad hexon peptide pools. PBMCs were obtained from 17 healthy 
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adults to study natural infection and longitudinally from 40 participants in 
Merck phase I Ad5 HIV vaccine studies, 10 of which were enrolled in the 
STEP trial precursor study using the same vector, dosing, and schedule used 
for the STEP study. T-cell phenotype and functionality were measured by 
polychromatic flow cytometry. We found that both CD4+ and CD8+ Ad5-
specific T-cells were universally present in subjects independent of their 
serostatus. Ad5-specific CD8+ T-cells exhibited an effector phenotype and 
produced the effector functions MIP1α and perforin whereas Ad5-specific 
CD4+ T-cells had an effector memory phenotype producing IL-2, IFN-γ and 
TNFα. Ad5-specific T-cells recognized both conserved and variable hexon 
epitopes making them highly cross-reactive with chimpanzee serotypes. Upon 
Ad5-based vaccination, Ad5-specific CD4+ T-cells were only transiently 
expanded and there were no differences in activation or mucosal homing 
marker expression between Ad5-seronegative and Ad5-seropositive subjects. 
These data suggest the increased risk of HIV infection observed in the STEP 
trial was not a result of Ad5-specific CD4+ T-cells. Ad5-specific CD8+ T-cells 
were also transiently expanded by Ad5-based vaccination, however, there 
were no changes in functionality. Together, these data suggest though pre-
existing Ad-specific T-cells may reduce vaccine efficacy, they should not 
represent a safety concern for the use of Ad-based vaccines.  
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Chapter 1: Introduction 
 
Vaccine History 
 The first vaccine was invented over 200 years ago in 1796 by Edward 
Jenner [1]. Prior to Jenner’s small pox vaccine, it was known that infection 
with small pox resulted in immunity from re-infection. As early as 430 BC 
women whom survived small pox infection would nurse children in order to 
transfer protection [2]. The practice of inoculation, or “to graft”, was also often 
practiced.  To inoculate, a pustule from an infected individual was sliced and 
the material subcutaneously introduced into an uninfected individual to induce 
immunity. This practice, however, had the risk of the inoculated subject 
developing systemic small pox or contracting other blood born diseases.  
Jenner developed his small pox vaccine after considering the stories of 
cow maids. Women believed that if they were infected with cow pox they 
would not become infected with small pox. Therefore, Jenner reasoned that 
the infecting agents must be similar enough so that infection with cow pox, 
which caused only mild local lesions, would protect from infection with the 
more devastating small pox. On May 14, 1796 Jenner inoculated 8-year-old 
James Phillips with material from a cow pox lesion on the hand of Sarah 
Nelms. When challenged with fresh small pox material a month later, Philips 
showed no signs of disease [1].  
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 It wasn’t until the late eighteen hundreds that a second vaccine was 
developed by Louis Pasteur to prevent rabies. The field of vaccinology was 
initially slow to develop but exploded in the 20th century. Since 1900, 21 
vaccines have been developed and there has been a 100% reduction in the 
morbidity of common childhood diseases including smallpox, diphtheria, polio 
and measles in the US [3]. Despite these great advances there are still 
several areas of infectious disease with an unmet need. 
 The World Health Organization (WHO) has identified tuberculosis, 
malaria, and HIV as diseases which should be targeted for accelerated 
vaccine development programs [4]. According to the WHO, approximately 33 
million people worldwide are infected with HIV/AIDS and 25 million people 
have died since the epidemic began in 1981 [5]. Although antiretroviral 
therapies (ART) are available to control HIV, only approximately 25% of HIV 
infected individuals in lower middle income countries who need ART qualify 
for it [6]. Additionally, only approximately 20% of individuals in sub-Sahara 
Africa who are HIV positive know they are infected [6]. With no cure for HIV, 
eliminating infection with the use of an effective HIV vaccine would have the 
largest impact on the global HIV pandemic. 
 
T-cell Vaccines 
 Traditional vaccine approaches utilized a killed or attenuated virus, 
protein, or toxin to induce neutralizing antibodies (nAb) that target the native 
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pathogen. The first HIV vaccine was designed as a traditional subunit vaccine 
utilizing a portion of the HIV envelope, gp160 [7].  Its study in humans began 
in 1987 and involved immunizing 138 subjects.  After ex-vivo studies showed 
a lack of broadly neutralizing HIV specific Abs, the HIV vaccine field turned to 
producing vaccines that induce cytotoxic T-cells (CTL) [8]. Researchers were 
further pushed towards a T-cell vaccine In 2003 when a Phase 3 trial of 
AIDSVAX, an HIV protein subunit vaccine designed to elicit neutralizing 
antibodies, proved ineffective at preventing HIV infection or lowering viremia 
in infected subjects [9,10]. 
T-cell vaccines for HIV have also been pursued because a number of 
studies have suggested CD8+ CTL are capable of controlling HIV infection. 
First, the generation of HIV specific CD8+ T-cells in infected subjects occurs 
at the same time as a decrease in acute viremia [11]. Second, depletion of 
CD8+ T-cells in SIV infected rhesus macaques resulted in an increase in 
viremia [12]. Third, several human class I MHC alleles are associated with 
control of virus and a slower progression to AIDS [13,14]. Finally, the 
immunological pressure exerted on HIV epitopes by CTL results in viral 
escape [15,16]. These findings indicate HIV specific CD8+ T-cells exert some 
control over viremia following infection. Therefore, a vaccine designed to elicit 
HIV-specific CTL given prior to HIV exposure may prevent the establishment 
of infection or more likely lower set point viremia, thus improving patient 
outcome and the transmission rates.  
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Figure 1: Adenovirus structure. www.nobelprize.org 
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Figure 2: Adenovirus hexon protein trimmer. Grey areas represent protein 
sequences conserved between diverse serotypes. Colored sequences represent the 7 loops 
that are hypervariable and define the 51 human serotypes. [17] 
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Adenovirus 
The primary platforms in development for generating CTL responses 
utilize viral vectors, the most potent among these appears to be recombinant 
adenoviruses (Ad). Ads are a group of icosahedral, non-enveloped viruses 
(Figure 1) [18]. There are currently 52 identified human Ad serotypes 
classified into 6 subgroups, A-F [19,20]. Subgroups are associated with 
specific tissue tropism in humans that are largely a result of individual 
subgroups utilizing unique cellular receptors differentially expressed 
throughout the body which are required for virus binding and entry [21]. The 
prevalent Ad5 serotype binds to the coxsackie adenovirus receptor (CAR) 
that is responsible for tight junctions between polarized epithelial cells [22].  
The CAR has been detected in human tissues including the heart, brain, 
pancreas, intestine, lung, liver, testis and prostate [22,23,24]. Virus binding 
requires the CAR to interact with the Ad fiber, one of the three major Ad 
capsid proteins [25]. The fiber protein is a long filament anchored by penton 
proteins [26,27]. The remainder and majority of the Ad capsid consists of 
trimmers of 240 hexon proteins [28,29].  Within the hexon protein there are 
seven hypervariable regions (Figure 2) [30,31]. The remaining ~80% of the 
hexon sequence are conserved between Ad serotypes (Figure 3) [32].   
The Ad capsid contains a double stranded, linear, DNA genome of 
approximately 34-43 kb (Figure 4). The genome contains two inverted 
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Figure 3: Adenovirus hexon sequence alignment. The Ad hexon amino acid 
sequence for human Ad5, chimpanzee Ad7 (Pan-7) and chimpanzee Ad6 (Pan-6). 
Hypervariable regions (HVR) are underlined. Sequences highlighted in grey are conserved 
among the three Ads[38]. 
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Figure 4: Wild type adenovirus genome [39].  
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terminal repeats (ITRs), and genes are grouped by early (E1A, E1B, E2, E3, 
E4, and E5) and late transcription (L1-L5) [33]. Upon infection, the early E1a 
gene is expressed first and acts as a promoter for the expression of the 
remaining early genes [34,35]. Therefore, deletion of the E1a gene results in 
a replication-incompetent virus [36,37]. The E1a gene is also responsible for 
promoting apoptosis, immune evasion, inducing host cell proliferation and 
blocking differentiation [40,41,42,43,44].  
Another critical Ad gene product is the E3 gene. E3 helps the host cell 
evade immune recognition through a number of mechanisms.  First, E3 
allows the virus to evade host immunity by preventing MHC class I transport 
to the cell surface where it can activate CD8+ T-cells [45,46,47].  Second, 
The E3 protein also interacts with the transporter associated with antigen 
processing (TAP) to prevent transport of viral peptides into the ER where they 
can bind MHC class I [48]. Third, E3 causes surface expression of the 
receptor internalization and degradation (RID) complex that blocks death 
receptor-induced apoptosis [49,50,51]. These critical immunomodulatory roles 
help Ad avoid recognition by CD8+ CTL and Ad-infected cell death, thereby 
ensuring production of new Ad virions. 
Ad infections generally occur during childhood and result in a range of 
acute symptoms depending on the infecting serotype [52]. For example, Ad5 
and other group C serotypes generally cause an acute respiratory infection 
resulting in symptoms such as a fever, headache and runny nose, whereas 
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infection with a group A or F virus results in gastrointestinal illness [53,54]. 
Rarely, Ad infection results in severe disease such as meningitis, though 
immunocompromised subjects are more susceptible to serious outcomes 
[55]. The prevalence of Ad infection varies by serotype and geographical 
region, with approximately 50% of US adults and 90% of African adults 
testing seropositive for Ad5 nAbs [56]. In contrast, only 5-15% of adults test 
seropositive for the rare serotype Ad35 [57]. Despite only acute symptoms, 
Ad maintains its genome in an episomal state in lymphoid tissues and has 
been detected in healthy adults years after infection [58,59,60]. 
 
Adenovirus Vector Design 
The potential of replication-defective Ad vectors for gene therapy and 
vaccine was recognized for several reasons. First, Ads have the ability to 
infect and persist in a wide variety of cells, including those that are not 
dividing [71,72]. Second, the transgene is expressed at a high level despite 
the observation that the viral genome does not integrate into the host 
genome. This eliminates a major regulatory concern as integration could 
result in insertional mutagenesis, increasing the patient’s risk of cancer 
[72,73]. Third, the virus is easily engineered replication-defective and grows 
well in large-scale cell culture. Finally, and perhaps most importantly, Ad 
vectors have been shown to induce potent and protective T-cell responses 
[74,75,76].  
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In order to design an appropriate and safe Ad vector for gene therapy 
or vaccines, several important considerations need to be made regarding 
vector serotype, Ad genome deletions and production. First generation Ad 
vectors based on Ad5 had the E1 gene deleted in order to render the vector 
replication-defective [96,97]. Molecular cloning is currently used to construct 
an E1-deleted vector by ligating the desired gene into a bacterial plasmid 
containing the entire Ad genome [98]. Successful recombinants can be 
selected by expression of herpes simplex virus thymidine kinase, green 
fluorescent protein or b-galactosidase [99,100,101]. After removing all 
bacterial sequences, vector can be grown in an appropriate production cell 
line [102,103,104]. There are a number of advantages to molecular cloning 
including the availability of commercially available kits for Ad5 vector 
production, ease in designing alternative serotype vectors, and the elimination 
of possible contaminants within primary Ad isolates used for vector 
construction through homologous recombination.  
For production of E1-deleted vector the E1 gene needs to be provided 
in trans. This can be accomplished by co-transfecting a vector which provides 
E1 or producing vector in human HEK 293 cells that contain the human Ad5 
E1 gene [102]. One regulatory concern with either method was the possibility 
for homologous recombination and the production of replication-competent Ad 
particles in a clinical product [105]. This can be overcome by using newer 
cells lines with truncated E1 sequences such as PER.C6 and N52/E6 or by 
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using an Ad vector based on non-human serotypes such as chimpanzee Ad 
[103,104]. Human Ad E1 will allow the production of non-human Ad vectors 
and the sequences differ enough to prevent homologous recombination in 
HEK 293 cells [103]. Importantly, some human Ad vectors such as Ad35 are 
not transcomplemented by Ad5 E1 and therefore require the modification of 
existing cell lines.  
Deleting the E1 gene allows for insertion of approximately 3.5 kb of 
transgene sequence [106,107,108]. In order to accommodate larger 
transgenes of up to 7.5 kb, E3 may also be removed [106,107]. Because E3 
is not required for Ad replication, E1- and E3-deleted vectors can be grown in 
cell lines containing E1. Further deletions include E2, E4 and a gutted vector 
containing only the Ad ITRs [109,110]. In addition to increasing the size of 
insert that can be used, deleting the E4 gene may reduce immunogenicity by 
eliminating expression of late gene products. To produce vectors with 
additional deletions in E2 or E4, cell lines must be created to provide the 
genes in trans [109,110]. Gutted vectors require use of a helper plasmid to 
produce vector in cell culture which increases the risk for homologous 
recombination and contamination with replication competent particles [111]. 
The vector serotype, deletions, and production method used should be 
carefully chosen to optimize gene therapy or vaccine efficacy and safety.  
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Adenoviruses in Gene Therapy 
Ads were first studied as a delivery vehicle for gene transfer starting in 
the early 1990s. Studies with several Ad constructs and inserts proved 
effective in animal models and were further studied in humans [61,62]. 
Among the most advanced testing of an Ad vector for gene therapy was for 
the correction of ornithine transcarbamylase (OTC) deficiency [63,64]. OTC 
disease is a single x-linked mutation that results in deficient urea synthesis 
[65]. Treatments for this disease are currently limited and there is a high 
morbidity and mortality associated with the disease, especially in 
homozygous males [66,67]. These characteristics make OTC deficiency an 
ideal candidate for gene therapy. 
Following successful and safe OTC gene therapy in mice and monkeys 
with an E1- and E4-deleted Ad vector, a pilot human study was initiated in 
1997 [63,68,69,70]. Seventeen subject with OTC mutations received 2x109 
viral particles (vp)/kg to 6x1011 vp/kg E1- and E4-deleted Ad5 expressing 
human OTC mRNA delivered via the hepatic artery [63]. Following gene 
transfer, less than 1% of hepatocytes were transduced and no significant 
improvements in ureagenesis were observed. Side effects included fever, 
fatigue, thrombocytopenia, anemia, decreased blood phosphate levels and 
acute biochemical liver damage.  
The outcome of the 18th subject was drastically different [64]. After 
receiving 6x1011 vp/kg vector he progressed to acute respiratory distress and 
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organ failure that ultimately lead to his death four days after treatment. It was 
later determined that Ad vector infusion had resulted in systemic immune 
activation which ultimately lead to the patients death. The demonstrated 
immunogenicity of Ad vectors made them a less desirable vector for gene 
therapy and the field has predominantly switched to the use of other vectors 
for gene correction purposes.  
 
Adenovirus Vaccines 
Although Ad were largely ineffective as vectors for gene therapy, their 
utility as vectors for CTL vaccines was quickly realized. Ad vaccine vectors 
have been tested most extensively in the setting of HIV. The validity of the 
Ad5 vector for an HIV-1 vaccine was supported by a large primate study 
comparing several prominent vaccine vectors that encoded SIV gag inserts. 
These were DNA, a modified vaccinia ankara virus vector, and a replication- 
incompetent Ad5 alone or in combination with the DNA vector [74]. Ad5 alone 
or Ad5 with a DNA prime produced the largest percentage of gag-specific 
CD8+ T-cells following vaccination. Following challenge with SHIV 89.6P, the 
DNA prime-Ad5 boost and Ad5 prime- boosted animals more effectively 
controlled set-point viral load reducing viruses to less than 103 vp/ml.  
In retrospect, this study was not stringently designed to test the 
efficacy of an Ad5 HIV-1 vaccine. First, only three monkeys were used in 
each vaccine group making it difficult to determine what was the average 
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response and what would be considered an outlier. Second, all Ad5- 
vaccinated monkeys had the Mamu*A01 MHC class I allele, which is naturally 
protective from SIV and SHIV infection [77,78]. Lastly, animals were 
challenged with SHIV 89.6P which appears to be more sensitive to T-cell 
based vaccine approaches [79].  
Following these results with Ad5-based vaccines in Rhesus Macaques; 
a Phase 1 human study was conducted. Starting May 1 2003, 259 subjects 
were enrolled in a dose-escalation safety and immunogenicity trial designated 
as the Merck 016 trial [80]. Subjects received 3x106 vp to 1x1011 vp Ad5 
expressing HIV-1 clade B gag, pol or nef at weeks 0, 4 and 26. There were no 
serious adverse events associated with vaccination. Subjects receiving 
3x1010 and 1x1011 vp had a similar immunogenicity with approximately 70% of 
subjects responding to an HIV insert 4 weeks after the last injection, and 
lasting up to week 78.  One concern raised by animal studies was that pre-
existing Ad5 nAb would limit vaccine efficacy, however this was not observed 
in seropositive subjects (nAb titer >200) in the 3x1010 vp dose group. 
Therefore, based on the immunogenicity and safety of a recombinant Ad5-
HIV-1 vaccine vector delivered by the IM route, it was decided to further test 
the vaccine in the phase IIb STEP trial with subjects at a high risk for HIV-1 
infection. 
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STEP trial 
The Phase IIb  trial was name STEP. It was a multi-center, 
randomized, double-blind and placebo-controlled trial aimed at establishing 
efficacy of the Ad5 HIV-1 gag/pol/nef vaccine.  All subjects were HIV-1 
negative but at a high risk for HIV infection. Half of the three-thousand 
enrolled subjects were Ad5 seronegative at baseline and half were 
seropositive. Subjects received three doses of 3x1010 vp at weeks 0, 4 and 
30. The trial was ended at a planned interim analysis by the data safety 
monitoring board on September 18th, 2007 because no efficacy was shown 
with the endpoints of either reduced rates of infection or reduced viral load in 
those infected as well as a possible increased risk of infection in vaccinated  
subjects. 
Analysis revealed the vaccine was immunogenic with 77% of subjects 
eliciting a T-cell response against at least one of the HIV insert antigens [81]. 
Immunogenicity, as measured by response rate, magnitude, or functionality of 
HIV-specific T-cells, was similar in cases (HIV infected during the trial) and 
non-cases (HIV-). If the vaccine was immunogenic why was it not effective at 
lowering viral load or preventing infection? One explanation might be that T-
cell responses were relatively modest with less than 1.0% of CD8+ T-cells 
responding to the vaccine antigens [82]. The quality of responding T-cells 
may also have been different than that required to prevent or modify HIV-1 
infection. Additionally, subjects recognized only three HIV antigens and it is 
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possible that the vaccine epitopes differed from the infecting virus sequence 
[81]. The final reason for why the Ad5 vaccine may not have been effective is 
CTL responses alone may not be sufficient to prevent HIV-1 infection.  
Subsequent analysis confirmed that there was an increased risk of 
infection in vaccinated subjects, however this was only seen in subjects who 
were Ad5 seropositive at baseline. In participants with no Ad5 pre-existing 
immunity (nAb titer <200 units) there was no difference in the level of HIV 
infection between placebos and vaccinees [82,83]. However, in participants 
with a pre-existing Ad5 nAb titer greater than 200 units, 21 cases of HIV 
infection were reported in those who received the vaccine versus only 9 
cases in those who received the placebo.  These results suggest that pre-
existing immunity to Ad5 as measured by nAb titers increased the risk of HIV 
infection following Ad5- based vaccination.  
One theory for the increased risk of infection in subjects with pre-
existing Ad5 immunity is that Ad5-specific CD4+ T-cells became activated 
upon vaccination. Activated CD4+ T-cells may then up-regulate the HIV-1 
receptor CCR5 or traffic to the gut mucosal tissue where they would be the 
primary targets for HIV infection and replication [84,85,86]. However, post-hoc 
analysis suggests Ad5-specific T-cell responses in Ad5-seropositive subjects 
were not the cause of the possible increased risk of HIV infection. The 
magnitude of Ad-specific CD4+ and CD8+ T-cell responses were actually 
lower in cases compared with non-cases and there were no differences in the 
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level of activation as measured by Ki67, Bcl-2 and CCR5. Unfortunately, 
samples from the STEP trial are limited by sparse peripheral blood 
mononuclear cells (PBMC) sampling and the lack of a baseline sample. The 
possibility that a vaccine may increase the risk of infection with the disease it 
was aimed at preventing highlights the need to understand T-cell specific 
responses not only to the transgene but also to the vector itself.  
 
Alternative Serotype Vaccines 
The efficacy of Ad-based vaccines is reduced by pre-existing Ad-
specific immunity. To avoid pre-existing immunity, vectors with a low 
seroprevalence are in development. These include human Ad26, 35 and 48, 
as well as chimpanzee AdC6, C7 and C68.  There are a number of 
differences between Ad5 and Ad35 that may affect vaccine efficacy. The 
worldwide seroprevalence of Ad5 is 40-90%, whereas Ad35 has a 
seroprevalence of only 2-16% [87]. However, due to a hexon sequence 
homology of close to 90% between Ad5 and Ad35, it is likely that pre-existing 
cross-reactive T-cells will recognize Ad35 even in seronegative subjects [38]. 
Unlike Ad5, Ad35 utilizes CD46 as a receptor for cellular entry [88]. CD46 is a 
complement regulatory protein expressed on all cell types including 
hematopoietic and dendritic cells that lack CAR expression. Despite different 
receptor usage, Ad35 and Ad5 both transduced muscle cells, showed limited 
biodistribution, were rapidly cleared, and showed similar toxicities when given 
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as an intramuscular injection [89]. This is in contrast to intravenous delivery in 
which Ad35 showed limited organ transduction and reduced toxicity 
compared with Ad5 [90]. 
Another approach to avoiding pre-existing immunity is the development 
of Ad vectors based on chimpanzee viruses such as AdC6 and AdC7. The 
seroprevalence of AdCs is less than 10%, which is even lower than the rare 
human serotypes [91]. AdCs are easily constructed by molecular cloning and 
can be grown in cell lines expressing Ad5 E1 without the risk of homologous 
recombination and the production of replication-competent vectors [92]. 
Based on E1 sequence homology, AdC6 and AdC7 are most closely related 
to the human Ad4, though sequence homology with Ad5 still high at 
approximately 90% [56,92]. Similar to Ad5, the chimp AdC6 and AdC7 utilize 
the CAR receptor, can be produced at high titers, and have similar levels of 
in-vivo infectivity [92,93]. Animal studies with AdCs have shown induction of 
potent insert-specific nabs and CD8+ T-cell responses prompting further 
development as vaccine vectors [94,95].  
 
 
Adenovirus Immunity 
Pre-existing Ad-specific immunity represents a major obstacle to the 
use of Ad vectors not only for gene therapy but also for Ad-based vaccines. 
Vaccination is less effective in animal models and humans if pre-existing Ad-
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specific nAbs are present [112,113]. In addition, nAbs can pose a problem for 
an Ad-based vaccine even in individuals without pre-existing immunity since 
an effective CTL vaccine will likely require at least one boost to generate 
sufficient levels of memory T-cells. The efficacy of a subsequent boosting 
injection may be limited by nAbs generated during the priming injection. It has 
been shown that significant levels of nAb result after a single Ad5 injection 
and can reduced transgene expression following a second injection [114]. 
Therefore, vaccination with an Ad-based vaccine for one infectious disease 
would also inhibit the efficacy of a subsequent Ad-based vaccine against 
heterologous pathogens.  
Ad-specific T-cells have also been shown to reduce the transgene- 
specific response to an Ad5-based vaccine [115]. Ad epitopes have been 
identified in humans for both CD4+ and CD8+ T-cells [116,117,118]. The 
conservation of these epitopes between the 52 serotypes suggests Ad-
specific T-cells will be highly cross-reactive [116,117,119,120].  This was 
partially confirmed in experiments in which human CTL cell lines created 
against an Ad5 vector were shown to kill target cells infected with diverse Ad 
serotypes [116,119]. CTL responses were targeted primarily against the 
hexon protein, which is the most abundant capsid protein delivered upon Ad 
vector administration [120]. 
Though nAb are serotype-specific, the cross-reactivity of Ad-specific T-
cells suggests they will be universally present in humans, as infection with at 
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least one Ad serotype occurs in most individuals. Indeed, several studies 
found Ad5-specific CD4+ and CD8+ T-cell responses irrelevant of 
seropositivity [59,82,121]. Additionally, T-cells that recognize simian Ad24 
were identified in 14 of 14 healthy subjects despite a seroprevalence of only 
10% in subjects from the same region [59]. Together, these data support 
some level of cross-reactivity in Ad-specific T-cells due to Ad sequence 
conservation among diverse serotypes.  
 
T-cells  
An important aspect of studying T-cells is characterizing their 
functionality and phenotype. The T-cell response to an infectious agent will 
generate a unique response consisting of cells making a variety of cytokines 
and expressing an assortment of surface receptors. By utilizing polychromatic 
flow cytometry, multiple T-cell functions can be measured including 
macrophage inflammatory protein 1 alpha (MIP1α), interferon gamma (IFN-γ), 
tumor necrosis factor alpha (TNFα), interleukin-2 (IL-2), perforin, and 
CD107a. These six functions are reliably assessed by flow cytometry and 
have unique immunological effects. MIP1α acts as a chemoattractant, 
recruiting inflammatory cells to the site of infection and mediating a TH1 
response [122,123]. IFN-γ and TNFα are both pro-inflammatory cytokines 
with several immunomodulatory and antiviral effects [124]. IL-2 is required for 
T-cell survival and the generation of memory responses [125]. Perforin is a 
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protein release by cytotoxic cells to mediate target cell killing [126]. CD107a is 
expressed in the membrane of secretory granules and is exposed upon 
degranulation. Staining for CD107a, therefore, serves as a surrogate for the 
release of cytotoxic granules from T-cells [127].  
To assess the magnitude of a T-cell response, IFN-γ as measured by 
ELISpot or flow cytometry is the gold standard assay often used 
[128,129,130]. However, by measuring IFN-γ alone, the total magnitude of the 
response may be underestimated, as not all responding cells produce IFN-γ, 
and IFN-γ alone is often not a correlate of the efficacy of a T-cell response 
[131,132]. A higher proportion of T-cells making both IFN-γ and IL-2 during 
HIV, hepatitis C virus, and M. tuberculosis infection correlated with better 
disease control than IFN-γ alone [133,134,135].  Furthermore, a more 
polyfunctional T-cell response consisting of IFN-γ, IL-2, TNFα, MIP1-β, and 
CD107a was associated with a slower progression to AIDS [136,137]. Lastly, 
a larger percentage of polyfunctional T-cells were observed following infection 
with viruses that are cleared or persist at a low level such as influenza, 
vaccinia virus, and cytomegalovirus, in contrast to chronic HIV infected 
patients where there is a high level of persistent antigen [138]. Though a 
highly functional T-cell response appears to be induced during natural viral 
infection, a highly functional Ad-specific T-cell response against a vaccine 
vector may be detrimental, since virally infected cells would be cleared before 
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transgene expression reaches a high enough level to stimulate a protective 
immune response. 
 
Memory Phenotype 
In addition to studying the functionality of T-cells, it is also critical to 
understand the memory phenotype of antigen-specific cells in order to better 
tailor an effective vaccine. T-cells newly differentiated from hematopoietic 
stem cells in the bone marrow travel to the thymus where they undergo 
positive and negative selection [139,140,141]. This process ensures cells are 
not reactive to self-proteins, are able to recognize peptides on self-MHC, and 
determines whether T-cells will be a CD4+ helper T-cell or CD8+ cytolytic T-
cell. Cells emerging from the thymus are considered naïve because they have 
yet to see their cognate antigen. Naïve T-cells can be distinguished because 
they express costimulatory receptors (CD27, CD28, CD45RA) which need to 
be engaged along with the T-cell receptor in order for cells to proliferate and 
differentiate into effector T-cells [142,143,144].  Naïve cells also express 
adhesion molecules such as CD62L and CCR7 that allow them to traffic 
through the lymph nodes where they may encounter their antigen [145,146]. 
Once T-cells encounter their antigen they become activated, 
proliferate, and can differentiate into an effector or memory cell. There are 
two theories for how memory cells develop [147]. One theory proposes that 
after an infection is cleared a subset of effector cells remain and mature into 
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memory cells, whereas the other theory proposes that when a naïve cell 
encounters antigen it proliferates and some progeny become effectors and 
some memory. Either way, memory and effector cells have unique 
characteristics and are both critical for an effective vaccine. 
Effector cells generated by vaccination are necessary to effectively 
fight off an infection by producing cytokines to activate innate immunity, 
providing B-cell help, and directly killing infected target cells.  These functions 
are mediated by the expression of cytokines such as IFN-γ, IL-17, and IL-2; 
chemokines such as MIP1α and rantes; and cytolytic proteins such as 
granzymes and perforin [148,149]. During an acute infection, effector cells 
proliferate to fight the pathogen and then undergo apoptosis once the 
infection is cleared [150,151]. In chronic infection they often become 
exhausted from constant antigen stimulation and gradually lose their effector 
functions [152,153]. Prolonged antigenic stimulation can also result in 
terminally differentiated cells that lose the ability to proliferate (CD57+) [154]. 
Once activated, cells down-regulate costimulatory surface proteins (CD27, 
CD62L) and up-regulate homing proteins (CCR5, α4β7) that allow them to 
enter the periphery and combat pathogens at the site of infection [155].  
In order for a vaccine to remain effective, long-lived memory cells must 
also be generated. Memory cells have a lower threshold for activation, create 
a larger pool of antigen specific T-cells, and produce different effector 
functions compared with naïve cells [156,157]. These characteristics allow for 
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the rapid production of effector cells and a quicker secondary response [158]. 
There are two subsets of memory cells which can be defined by the 
expression of CCR7 [156]. Central memory cells express CCR7 allowing them 
to circulate through the secondary lymphoid organs where they have a higher 
chance of encountering antigens and initiating an immune response.  Effector 
memory cells lacking CCR7 patrol areas of inflamed tissue and have 
immediate effector capabilities to eliminate pathogens.  
Though the phenotype of a vaccine-induced T-cell response is critical 
for efficacy and long-term protection, the quality of the response may be just 
as important. Studies of an Ad-based Leishmania major vaccine in mice 
showed a milder disease upon infection with L. major when a lower dose of 
the Ad vaccine was administered [159]. The degree of protection did not 
correlate with the magnitude of insert-specific IFNγ+ CD4+ T-cells but did 
correlate with the quality of the response. Mice given the low Ad dose had 
more polyfunctional CD4+ T-cells expressing IL-2, TNFα, and IFN-γ compared 
with mice given the high dose. Additionally, triple positive CD4+ T-cells 
produced more IFN-γ and TNFα on a per-cell basis compared with single and 
double positive cells, which may explain why having more triple positive cells 
correlated with better control. Though this model defined polyfunctional TH1 
CD4+ T-cells as a correlate of L. major control, no correlates of protection 
have been defined for vaccine induced CD8+ T-cell responses. 
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Thesis Goals 
The failure of Ad vectors in gene therapy and the STEP trial highlights 
the need to understand how pre-existing Ad-specific immunity affects the 
efficacy and safety of Ad vector-based gene delivery. We aimed to 
characterize the magnitude, phenotype, functionality, and cross reactivity of 
Ad-specific T-cells following natural infection and vaccination. We 
hypothesized that Ad-specific T-cells would be present in most donors and 
cross-react with diverse serotypes based on sequence homology between Ad 
serotypes. Ad-specific T-cells would have an effector and effector memory 
like phenotype due to continual stimulation by persistent Ad virus and repeat 
infection with any of the 52 human serotypes. Likewise, vaccination with Ad5 
vector would stimulate pre-existing Ad-specific CD4+ and CD8+ T-cells to a 
similar extent in baseline Ad5-seropositive and Ad5-seronegative subjects.  
There are several facets of this study that are critical to our 
understanding of Ad T-cell immunity. First, studying a heterologous human 
population is essential for understanding Ad-specific T-cells as animal models 
do not replicate the continual Ad re-stimulation human T-cells receive from 
persistent virus and periodic infection. Second, by using the most advanced 
flow cytometry techniques we can precisely characterize the detailed 
phenotype and functionality of Ad-specific T-cells. Third, we developed a 
novel stimulation assay that allows us to detect T-cell responses to the entire 
Ad vector directly ex-vivo with minimal cell manipulation, thereby reducing the 
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chance for responses that are an assay artifact. Lastly, we have access to 
very limited and extensive samples from the Merck phase I safety trial using 
the same vector, dose and schedule as used for the STEP trial.  These 
samples are critical for understanding the possible increased risk of infection 
in Ad5-seropositive patients as samples from the STEP trial are limited and 
lack a baseline time point. This work represents the most extensive 
characterization of human Ad-specific T-cell responses performed to date. 
The result of this analysis suggests important considerations for future T-cell 
based vaccine design. 
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Chapter 2: Materials and Methods 
 
Subjects 
 Peripheral blood mononuclear cells (PBMCs) were obtained by aphaeresis of 
HIV and HCV negative adult healthy donors by the University of Pennsylvania 
Center for AIDS Research Immunology Core, under the institutional 
guidelines required for conduct of experiments on human samples.  
 For studies involving Ad5 vaccination we obtained frozen PBMCs from 
various Merck phase I Ad5 HIV vaccine trials (Table 3). Written informed 
consent was obtained from participants. The vaccination dose and schedule 
for the seropositive and seronegative groups were identical to that used in the 
phase II STEP trial.  PBMCs were obtained from study weeks 0, 4, 8, 18, 26, 
30, 42, 52 and 78.  
 
Vector 
 Human adenovirus 5 (Ad5), chimpanzee adenovirus 6 (AdC6) and 
chimpanzee adenovirus (AdC7) vectors were prepared using previously 
described methods [160]. For cell stimulation we used an E1-deleted Ad5 
vector that expressed the rabies virus glycoprotein [32,161]. The Ad5 vector 
was grown on HEK293 cells in DMEM supplemented with 10% fetal calf 
serum, antibiotics and glutamine [162]. Vectors were purified by CsCl 
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gradients and quality controlled (infection unit to vp ratios, lack of replication 
competent Ad5 virus, genome integrity, lack of LPS contamination, sterility) 
 
Neutralizing Antibody Titer 
Ad5 neutralizing antibody titers were measured by Lisa Kierstead at 
Merck Research Laboratories as previously described [163]. Briefly, 2x104 
HEK293 cells per well in a 96 well plate were seeded for 2 days. Ad-secreted 
alkaline phosphatase (SEAP) was incubated for 1 hour at 37 °C either alone 
or with serial dilutions of serum then added to the 95-100% confluent 293 
cells and incubated for 1 hr at 37 °C. Supernatant was then removed and 
replaced with 10% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle 
Medium (DMEM). SEAP expression was measured 24 ± 2 hrs later with the 
chemiluminescent substrate from the Phospha-Light™ kit. (Applied 
Biosystems).  
 
Antibodies 
We obtained directly conjugated antibodies from the following: BD 
Biosciences: TNFα (Pe-Cy7), IFN-γ (Alexa700); Caltag: CD14 (APC-
Alexa750), CD19 (APC-Alexa750), β7 Integrin (PeCy5), CD49d α4 (APC), 
Ki67 (Fitc), CD103 (FITC) and CD4 (Pe-Cy5.5); Beckman Coulter: CD8 
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(ECD), CD27 (Pe-Cy5); eBioscience CCR7 (APC-Alexa750) and R&D 
systems. 
 
Whole Vector Stimulation 
To measure responses to the Ad5, AdC6 and AdC7 vectors, 2x106 
PBMCs were incubated overnight with 1x1011 vp and costimulatory antibodies 
(αCD28 and 49d, 1 µg/ml; αCD28 alone for mucosal marker staining, BD 
Biosciences) at 37 °C and 5% CO2 in 1 ml R10 media (RMPI 1640 with 10% 
heat inactivated FBS, 100 U/ml Penicillin, 100 µg/ml streptomycin sulfate and 
1.7 mM sodium glutamate) in 5 ml BD Facs tubes
.  
We stimulated a positive 
control with Staphylococcus enterotoxin B (SEB, 1 mg/ml; Sigma-Aldrich) and 
a negative control received only costimulatory antibodies. The following 
morning we added Monensin (Golgi Stop, 0.7 µg/ml; BD Biosciences) and 
Brefeldin A (1 µg/ml; Sigma-Aldrich) to each sample and incubated the cells 
for six hr at 37 °C and 5% CO2 before staining.  
 
Peptide Stimulation 
Peptide libraries were stimulated for Ad5, AdC6 and AdC7 hexon 
sequence consisting of 15 amino acids peptides that overlap by 11 amino 
acids. Peptides were pooled into five groups of approximately 40 peptides 
each. One pool consisted of sequences in the variable regions of the hexon 
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and the other four pools were linear pools of the conserved regions 
(Appendix).  
 To stimulate cells, PBMCs were thawed or obtained from fresh 
aphaeresis and rested overnight at 2x106 cells/ml in R10 media (RMPI 1640 
with 10% heat inactivated FBS, 100 U/ml Penicillin, 100 mg/ml streptomycin 
sulfate and 1.7 mM sodium glutamate) in filter top T-flasks. The following 
morning, cells were counted and resuspended at 1-2x106 cells/ml in R10 
media. Costimulatory antibodies (αCD28 and 49d, 1 µg/ml) were added to 
cells and 1 ml cells were aliquoted to BD Facs Tubes containing 5 µl (2 µg/ml 
each peptide in DMSO) of a given peptide pool. A negative control received 
only co-stimulatory antibodies and a positive control was stimulated with 
Staphylococcus enterotoxin B (SEB, 1 µg/ml; Sigma-Aldrich).  
 
Staining 
Following vector or peptide stimulation samples were washed in 
phosphate buffered saline (PBS) and stained for viability (Aqua live/dead 
amine reactive dye; Invitrogen). To determine viability the aqua dye tube was 
reconstituted in 12.5 µl DMSO and stored at -20°C. This stock was then 
diluted 1:60 in PBS. PBS was decanted following the wash and cells in facs 
tubes were stained with 5 µl for 10 min at room temperature in the dark. 
Following live dead staining surface antibodies were added for 20 min at 
room temperature in the dark (Table 2-4). Surface stain mixes were made up  
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Target Color Clone Manufacturer Catalog 
Number 
Stain  
Aqua Live 
Dead 
Aqua NA Invitrogen L34597 Pre-stain 
CD3 QD585 OKT3 In Lab American 
Type Culture 
Collection 
intracellular 
CD4 PeCy5.5 S3.5 Caltag MHCD0418 surface 
CD8 Texas Red PE 3B5 Coulter 6604728 surface 
CD27 PeCy5 1A4LDG5 Coulter 6607107 surface 
CD45RO QD 705 UCHL1 In Lab AbD Serotech surface 
CD57 QD565 TB01 In Lab AbD Serotech surface 
CD14 APCAlexa750 TüK4 Caltag MHCD1427 surface 
CD19 APCAlexa750 SJ25-C1 Caltag MHCD1927 surface 
IL-2 APC MQ1-17H12 R&D 554567 intracellular 
IFN-g Alexa700 L11370 BD 557995 intracellular 
TNFa PeCy7 MAb11 BD 557647 intracellular 
Perforin PacBlue B-D48 In Lab Diaclone intracellular 
MIP1a PE 93342 R&D IC2701P intracellular 
CD107a FITC H4A3 BD 555800 Pre-stain 
Table 1: Normal Donor Functionality Staining 
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Target Color Clone Manufacturer Catalog 
Number 
Stain 
Aqua Live 
Dead 
Aqua NA Invitrogen L34597 Pre-stain 
CD3 QD585 OKT3 In Lab American 
Type Culture 
Collection 
intracellular 
CD4 PeCy5.5 S3.5 Caltag MHCD0418 surface 
CD8 Texas Red PE 3B5 Coulter 6604728 surface 
CD27 PeCy5 1A4LDG5 Coulter 6607107 surface 
CD45RO QD 705 UCHL1 In Lab AbD Serotech surface 
CD57 QD565 TB01 In Lab AbD Serotech surface 
CD14 APCAlexa750 TuK4 Caltag MHCD1427 surface 
CD19 APCAlexa750 SJ25-C1 Caltag MHCD1927 surface 
IL-2 APC MQ1-17H12 R&D 554567 intracellular 
IFN-g Alexa700 L11370 BD 557995 intracellular 
TNFa PeCy7 MAb11 BD 557647 intracellular 
Perforin PacBlue B-D48 In Lab Diaclone intracellular 
MIP1a PE 93342 R&D IC2701P intracellular 
Ki67 FITC 35 BD 612472 intracellular 
Table 2: Vaccine Functionality Staining 
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to 50 µl per tube in Facs Buffer (PBS with 1% fetal bovine serum and 0.1% 
sodium azide). Following surface staining cells were washed once in facs 
buffer then permeabilized and fixed by adding 250 µl Cytofix/Cytoperm (BD 
Biosciences) for seventeen min at room temperature in the dark followed by a 
wash with perm wash buffer (BD Biosciences). Cells were then stained with 
intracellular fluorochrome-labeled antibodies for 1 hour at room temperature 
in the dark. Intracellular staining antibodies were made up to a final volume of 
50 µL per tube in perm wash buffer. Following staining cells were washed 
with perm wash buffer, fixed (2% paraformaldehyde in PBS) and stored at  
4°C in the dark until analysis. All antibodies were titrated to determine the 
optimal staining. 
 
Flow Cytometry 
We analyzed cells on a modified LSR II flow cytometer (BD 
Immunocytometry Systems) with 200,000 to 1,000,000 events collected per 
sample. Data was analyzed using FlowJo 8.7 (TreeStar). Cells were initially 
gated to remove doublets followed by a lymphocytes gate on forward scatter 
area versus side scatter area. We removed dead cells by gating CD3 versus 
Aqua blue removing cells that are Aqua blue bright. Contaminating CD14+ 
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and CD19+ cells were also removed before gating sequentially on CD3+, and 
CD8+/CD4+ and CD4-/CD8- versus IFN-γ to account for receptor down-
regulation. We then made a gate for each respective function and the 
Boolean gating platform was used to create the array of possible functional 
combinations. Data are reported after background subtraction of the no 
stimulation condition.  
 
Statistics 
For normal donor samples, variability in the assay was tested using 
Levene’s robust variance test with Brown and Forsythe’s 10% trimmed mean 
alternative. This method is robust to non-normality in the data. Analyses were 
conducted using Stata MP 10.0.  The T-cell response to different vectors and 
peptide pools were compared using a Friedman Statistic. This method is 
similar to an ANOVA for non-parametric matched data. When two groups 
were compared, a Wilcoxon's sum rank test, which is similar to a t-test for 
non-parametric data, was used. These statistics were performed in Graphpad 
Prism. 
 For vaccine samples mixed effects models were performed to test for 
group differences over time. Mixed effects models were also used for 
comparisons between baseline and subsequent time points within each 
group. Time was considered to be a discrete variable, lessening the power of 
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these tests compared to tests where time is a continuous variable. Spearman 
correlations were used to test the relationship between Ad5 nAb titers and  
T-cell functions at baseline. Correlations over the entire time period were 
computed using partial correlation coefficients controlling for individual subject 
effects in the repeated measurements. All data was log transformed using 
base e. Vaccine statistics were performed by Sarah Ratcliffe from the 
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics. 
 
CFSE Staining 
Fresh PBMCs obtained from aphaeresis were centrifuged at 1500 
RPM for six minutes and resuspended at 5x106 cells/ml in sterile PBS. A 
stock vial of CFSE was prepared by reconstituting a CFSE dye vial 
(Invitrogen) with 18 ml DMSO. CFSE stock (0.5 µl/ml) was added to cells for 
10 min at 37°C.  Cells were then quenched with 10 ml ice-cold R10 media 
and incubated on ice for 10 min before washing twice in R10 media. Cells 
were counted and resuspended at 2x106 cells/ml  in R10 media and 
stimulated with 1x1011 vp Ad5 or 2 µl Ad5 lysate for 6 days. On the 6th day 
cells were restimulated with Ad5 vp or lysate and 3 µl/ml αCD49/CD28d. After 
two hours, 1 µl/ml brefeldin A and 0.7 µl/ml monensin were added to each 
tube and the cells incubated at 37°C for an additional two hours before 
staining as indicated above.  
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Chapter 3: Adenovirus-Specific Human T-cells 
are Pervasive, Polyfunctional, and Cross 
Reactive 
 
Abstract 
Pre-existing immunity to adenovirus (Ad) reduces the efficacy of Ad-
based vaccines. The goal of this study was to define the prevalence, 
magnitude, functionality and phenotype of Ad-specific human T-cells directly 
ex vivo.  To study the magnitude of T-cell responses to Ad, we developed a 
highly reproducible whole Ad vector stimulation assay for use with 
polychromatic flow cytometry. Ad-specific CD4+ and CD8+ T-cells were 
detected in all 17 human subjects tested and were capable of proliferating 
upon restimulation. Ad-specific CD4+ T-cells were primarily monofunctional 
CD4+ T-cells that produced IL-2, IFN-γ or TNFα and expressed the memory 
markers CD27 and CD45RO. In contrast, Ad5-specific CD8+ T-cells were 
more polyfunctional, expressing effector-like combinations of IFN-γ, MIP1α 
and perforin, and generally lacked CD27 and CD45RO expression.  Ad-
specific CD4+ and CD8+ T-cell responses against chimpanzee-derived AdC6 
and AdC7 were found in all subjects, indicating the commonality of cross-
serotype reactivity of Ad-specific T-cells. This cross-reactivity is due in part to 
extensive CD4+ and CD8+ T-cell recognition of hexon regions conserved 
between multiple Ad serotypes.  The prevalence, cross-reactivity and effector- 
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like functions of Ad-specific T-cells in humans may affect the efficacy of Ad 
vector-based vaccines by eliminating vector infected cells even when rare 
serotype Ad vectors are employed. 
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Introduction 
Adenovirus (Ad) vectors are commonly used as vaccine carriers 
because of their ability to induce insert-specific CD8+ T-cell responses. 
However, pre-existing Ad-specific immunity represents a major obstacle for 
Ad-based vaccines [76,113]. In animal models and humans, vaccination is 
less effective in the presence of neutralizing antibodies (nAb) [80,112,113]. It 
has also been shown that significant levels of nAb are generated after a 
single Ad5 injection, thereby reducing the efficacy of a homologous vaccine 
boost [114]. The prevalence of nAb to the commonly used Ad5 varies 
worldwide, and was shown to be as high as 90% in Africa.  Seroprevalence of 
the other 52 identified human Ads also fluctuate globally with the occurrence 
of natural infection. To avoid the potential limitations imposed by pre-existing 
immunity, vectors based on alternative Ad serotypes are in development, 
including Ad26, 35, 48, and the chimpanzee-derived AdC6, C7, and C68.  
Neutralizing Ab titers to these various rare Ad serotypes are typically low in 
humans, with seroprevalence to AdC6 and AdC7 less than 5% of adults in the 
United States and less than 10% seropositive in equatorial Africa, the natural 
habitat for chimpanzees [91]. 
Although the prevalence and effects of Ad-specific nAb on vaccine 
efficacy have been studied, little work has been done to characterize the 
naturally occurring T-cell response to Ad, or the potential of Ad-specific  
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T-cells to influence Ad-based vaccine efficacy.  Ad-specific CD8+ T-cell 
responses can limit the effectiveness of Ad-vectored vaccines in animal 
models [31,114], presumably due to the direct elimination of vector-
transduced antigen presenting cells.  Such studies, however, have not been 
performed in the setting of natural Ad infection in humans.  Ad-specific T-cells 
have been detected ex vivo in humans, both before and after Ad vector 
vaccination, in peripheral blood and mucosal tissues [59,82,116,117,164].  
Several MHC class II-restricted CD4+ T-cell epitopes have been identified in 
the Ad5 hexon, residing primarily in regions conserved between disparate Ad 
serotypes, such as the HLA-DP4 restricted CD4+ T-cell epitope (hexon 910-
924) [117,118,165]. MHC class I restricted CD8+ T-cell epitopes have also 
been identified in the Ad hexon, penton, and fiber [117,120].  Responses to 
Ad appear to be almost ubiquitous in the human population [59,82];
 
however, 
beyond simple quantification, little is known regarding the functionality and 
phenotype of Ad-specific CD4+ and CD8+ T-cells in humans.  Moreover, while 
serotype cross-reactivity has been noted for both Ad-specific CD4+ and CD8+ 
T-cells, it is unclear whether Ad-specific T-cells cross-reacting with a 
disparate Ad serotype will function in a similar manner.
 
 To address these issues, we have developed a highly reproducible 
polyfunctional flow cytometry-based assay to quantify and characterize Ad-
specific CD4+ and CD8+ T-cells directly ex vivo from human peripheral blood 
lymphocytes.  Herein, we describe the functional and phenotypic properties of 
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human Ad-specific T-cells against human Ad5 and cross-reactive responses 
against chimpanzee-derived AdC6 and AdC7. 
 
Results 
Optimization of Ad particle stimulation for Ad-specific T cell responses 
by intracellular cytokine staining  
Previous studies of Ad-specific T-cell responses have focused on 
examining Ad hexon protein-specific T-cell responses using ELISpot assays.  
However, by using only hexon peptides, T-cells specific for other Ad proteins 
are missed and the magnitude of Ad-specific T-cells are underestimated. To 
better quantify and characterize human Ad-specific T-cell responses, we 
developed a stimulation procedure using intact Ad particles, followed by a T-
cell flow analysis using standard intracellular cytokine-staining (ICS) assay.  
To begin, we determined the optimal concentration of intact Ad particles to 
maximize expression within peripheral blood mononuclear cells (PBMC) for 
presentation to T-cells.  We incubated an Ad5 vector expressing green 
fluorescent protein (GFP) at various concentrations ranging from 1x109 vp to 
1x1011 vp with PBMC for 18 hrs and assessed GFP expression in B cells 
(CD19+), monocytes (CD14+),  
T-cells (CD3+/CD4+/CD8+), or the remaining PBMCs negative for these 
markers. After an overnight incubation, GFP was detected in CD14+ 
monocytes and CD19+ B cells in a dose dependent manner (Figure 5A). No  
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Figure 5: Measuring adenovirus specific T-cell responses following 
whole vector stimulation. PBMCs from healthy adults were cultured overnight at 37°C 
in 5% CO2 with Ad5 vector and costimulatory antibodies αCD28 and αCD49d. The following 
morning golgi secretion inhibitors brefeldin A and monensin were added for 6 hours before 
standard intracellular cytokine staining. A) PBMCs were incubated with 1x109-1x1011 vp Ad5 
expressing green fluorescent protein (GFP).  The upper graphs show GFP expression in 
CD14+ monocytes and CD19+ B-cells, and the lower graph shows expression in CD3+ T-cells. 
B) PBMCs were stimulated with 1x109-1x1011 vp Ad5 vector and CD4+ and CD8+ T-cell 
responses were measured by IFN-γ production.  C) Ad-specific IFN- γ + CD4+ and CD81 T-cell 
responses were measured in seven donors following stimulation with 1x109-1x1011 vp Ad5. 
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GFP was expressed in other cell types.  Along with increasing vector 
concentration we also detected an increase in Ad-specific CD4+ and CD8+  
T-cell responses as measured by IFN-γ production (Figure 5B). To confirm 
the optimal vector dose for T-cell stimulation the vector titration was repeated  
using PBMC from 6 normal donors. Optimal IFN-γ expression was observed 
at the maximal dose of 1 x 1011 Ad particles/million PBMC (Figure 5C).  
 
Polyfunctional analysis of Ad-specific T-cell responses 
Having established the optimal conditions to detect IFN-γ producing 
Ad-specific T-cells using whole Ad particles, we next adapted the procedure 
to a polychromatic flow cytometry panel that simultaneously detects T-cell 
memory phenotype and 5 unique effector functions, i.e. IL-2, IFN-γ, TNFα, 
MIP1α, and perforin, along with standard T-cell lineage markers, and 
exclusion markers.  To ensure that we were detecting only Ad-specific T-cells 
and minimizing background, we followed a strict gating strategy that removes 
dead cells as well as CD14+ monocytes and CD19+ B cells.  We were able to 
detect Ad-specific CD4+ and CD8+ T-cells capable of eliciting multiple 
functions after stimulation (Figure 6).  We next re-evaluated our Ad vector 
titration to determine if there were differential functional responses based on 
vector dose. The Ad-specific T-cell response was similar at all vector 
concentrations for CD8+ T-cells, which produced a combination of IFN-γ,  
 44
 
Figure 6: Gating strategy for measuring Ad-specific T-cell responses. 
Gating strategy for determining Ad-specific CD4+ and CD8+ T-cells producing IL-2 IFN-γ 
MIP1α, Perforin and TNF α 
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Figure 7: Adenovirus particle stimulation for measuring polyfunctional 
Ad-specific T-cell responses. A) Polyfunctional CD4+ and CD8+ T-cell responses 
following stimulation with 1x109-1x1011 vp Ad5. B) PBMCs from a single donor were 
stimulated with 1x1011 vp Ad5 on 7 different days to test the reproducibility of the whole vector 
stimulation assay. The percentage of CD4+ T-cells producing IL-2, IFN-γ and TNF α was 
compared following Ad vector and positive control streptococcus enterotoxin B (SEB) 
stimulation. The degree of variability was significantly less (p<0.05) following Ad stimulation 
compared with SEB. 
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TNFα and perforin with small amounts of IL-2. CD4+ T-cells predominantly 
produced IFN-γ, IL-2, and TNFα (Figure 7A, average of six subjects). At 
1x1011 vp Ad5 the percentage of CD4+ and CD8+ T-cell producing only IFN-γ 
was appreciably higher than the other functional combinations.  Finally, we 
examined the reproducibility of the assay system in the setting of 
simultaneous IL-2, IFN-γ, and TNFα production (Figure 7B).  Using 
cryopreserved samples, we measured the Ad-specific T-cell response at the 
1x1011 Ad particle dose with the same batch of PBMC obtained from a single 
donor on seven separate days. The variability in Ad-specific CD4+ and CD8+ 
cell frequency producing IL-2, TNFα, and IFN-γ was low, and  
significantly lower than the range of variability observed for the superantigen 
positive control (SEB, p<0.05).  
 
Ad5-specific CD4+ and CD8+ T cells are common in humans 
We next assessed the functionality and phenotype of Ad5-reactive  
T-cells in 17 healthy adults. CD4+ and CD8+ T-cell responses to Ad5 were 
detected in all subjects. Most subjects had primarily monofunctional CD4+  
T-cells that produced IL-2, IFN-γ or TNFα (Figures 8A, C). In contrast, Ad5-
specific CD8+ T-cells were more polyfunctional, expressing effector-like 
combinations of IFN-γ, MIP1α and perforin (Figures 8B, D). With the  
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Figure 8: Adenovirus 5 specific T-cell responses are common in 
humans. We assessed the functionality and phenotype of Ad5-specific T-cells in 17 healthy 
adults by stimulating PBMCs with whole Ad5 vector and performing intracellular cytokine 
staining. A) The percentage of Ad5-specific CD4+ T-cells producing IL-2, IFN-γ MIP1α, 
Perforin and TNFα. B) The percentage of Ad5-specific CD8+ T-cells producing IL-2, IFN- γ, 
MIP1α, perforin and TNFα.  C) The average polyfunctional Ad5-reactive CD4+ T-cell 
response from 17 donors. D) The average polyfunctional Ad5-reactive CD8+ T-cell response 
from 17 donors 
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Figure 9: Memory phenotype and proliferation of Ad5-specific T-cells. We 
assessed the phenotype, functionality and proliferation of Ad5-specific T-cells by stimulating 
PBMC with replication defective Ad5 vector. Proliferation was accessed by CFSE dilution 
after 6 days. A) Ad5-reactive CD4+ and CD8+ T-cells proliferate in response to Ad5 
stimulation. The percentage of CFSE low dividing cells is shown following no stimulation or 
stimulation with Ad5 vector. B) Memory phenotype of Ad5-specific CD4+ and CD8+ T-cells. 
Memory phenotype of all CD4+ and CD8+ T-cells is shown in grey. Red dots represent Ad-
specific cells positive for IL-2, IFN-γ, MIP1α, Perforin and or TNFα. Ad5-specific CD4+ cells 
are primarily central memory-like (CD27+CD45RO+) and effector memory (CD27-CD45RO+) 
phenotypes. Ad5-specific CD8+ T-cells are primarily effector (CD27-CD45RO-) and central 
memory like (CD27+CD45RO+) phenotypes.  C) Memory phenotype of proliferating Ad-
specific cells. Memory phenotype of all T-cells after a 5-day stimulation with Ad5 is shown in 
grey. CFSE low T-cells are shown in red. CD4+ T-cells are on the left and CD8+ T-cells are on 
the right. 
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exception of monofunctional responses, nearly all Ad5-specific CD8+ T-cells 
produced perforin together with at least one other function (Figure 8D).   
Ad5-specific CD4+ and CD8+ T-cells were also capable of proliferating 
upon stimulation (Figure 9A).  Ad-specific CD4+ T-cells generally exhibited a 
central memory-like phenotype (CD27+CD45RO+) with a small contribution of 
effector memory (CD27-CD45RO+) cells (Figure 9B, left panel).  In marked 
contrast, the majority of Ad-specific CD8+ T-cells displayed an effector-like 
phenotype (CD27-CD45RO-), with a smaller contribution of central memory-
like cells (Figure 9B, right panel). In contrast, proliferating Ad-specific CD4+  
and CD8+ T-cells had primarily a central memory-like phenotype after 6 days 
of stimulation (Figure 9C).  
 
Ad5 hexon-specific responses are commonly observed in humans and 
are directed against both conserved and variable regions 
 Next, we determined whether Ad5 hexon-specific responses were 
directed against conserved or variable hexon regions. We also assessed the 
functionality of responses to the different regions of hexon. The latter  
analysis was conducted to elucidate differences in responses to the constant 
regions that had presumably been recalled repeatedly due to infections with 
different Ad serotypes and those to the variable loops that presumably have a 
different stimulation history.   Starting with overlapping 15-mer peptides 
spanning the hexon amino acid sequence, we divided the conserved regions 
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Figure 10: Ad5-specific T-cells recognize variable and conserved 
regions of the hexon. We assessed the functionality and phenotype of Ad5-
specific T-cells in 17 healthy adults by stimulating PBMCs with overlapping 15mer 
Ad5 hexon peptides. Approximately 44 peptides were combined into each of 5 pools: 
1 for all sequences in the variable regions of the hexon, and 4 containing linear 
sequences within the conserved regions of the hexon. The percentage of CD4+ and 
CD8+ T-cells responding to the conserved 1 (C1), conserved 2 (C2), conserved 3 
(C3), conserved 4 (C4), and variable  (V) hexon pools are shown.  Cells staining 
positive for IL-2, IFN-γ, MIP1α, Perforin and or TNF α were summed to compute the 
total percentage of responding cells. CD4+ responses are depicted in white bars and 
CD8+ responses in grey. Center line represents the mean with whiskers depicting the 
standard error. 
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into 4 linear pools of ~ 44 peptides each (C1-C4), and made a single pool 
consisting of peptides from variable (V) regions.  We could readily detect 
CD4+ T-cell responses to all 5 pools (Figure 10, open bars), indicating that 
CD4+ T-cells can recognize epitopes spread throughout the hexon, with the 
largest responses in the C2, C3, and V pools. There was no significant 
difference in the summation of the total response between the C2 and C3 
pools compared with the V pool, while responses to the C1 (p<0.001) and C4 
(p<0.02) pools were significantly lower. CD8+ T-cells also responded potently 
to Ad hexon (Figure 10, grey bars).  The magnitude of responding CD8+ T-
cells was higher than that of CD4+ T-cells with the largest responses against  
the C3 and V pool.  
Both CD4+ and CD8+ T-cells had similar functionality following 
stimulation with conserved and variable Ad hexon pools (Figure 11). Ad-
specific CD4+ T-cells produced little perforin, while IL-2, IFN-γ, MIP1α, and 
TNFα dominated the responses.  While there were multifunctional responses 
(two or more functions simultaneously), the bulk of Ad-specific CD4+ T-cells 
were monofunctional (Figure 11A, top), producing either IFN-γ, IL-2, TNFα, or 
MIP1α only (Figure 11B, top).  The CD4+ T cell responses against the hexon 
peptide pools were similar in functionality compared to the whole Ad vector, 
with the exception that whole Ad vector responses were dominated by IFN-γ 
production, while responses elicited by hexon peptides tended to skew to  
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Figure 11: Polyfunctionality of Ad5-specific T-cells is similar to variable 
and conserved regions of the hexon. We assessed the functionality and phenotype 
of Ad5-specific T-cells in 17 healthy adults by stimulating PBMCs with overlapping 15mer 
Ad5 hexon peptides. Approximately 44 peptides were combined into 5 pools: 1 for all 
sequences in the variable regions (V) of the hexon, and 4 containing linear sequences (C1-
C4) within the conserved regions of the hexon A) Percentage of Ad-specific cells with a 
polyfunctional response. Pies represent all responding Ad-specific cells making IL-2, IFN- γ, 
MIP1a, Perforin and or TNFα following stimulation with Ad5 vector or Ad5 hexon pools C1, 
C2, C3, C4 or V. Each slice represents the proportion of the cells producing four of five 
cytokines (blue), three of five (green), two of five (yellow) and one of five (orange). B) 
Percentage of Ad-specific cells with a polyfunctional response. Bars represent the 
percentage of CD4+ (top) and CD8+  (bottom) T-cells making each combination of IL-2, IFN- 
γ, MIP1α, Perforin and or TNFα following stimulation with Ad5 vector (blue) or Ad5 hexon 
pools C1 (red), C2 (neon green), C3 (orange), C4 (pink) or V (dark green). Plus signs 
represent cells staining positive (+) for each cytokine. 
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TNFα production (Figure 11B, top).  This difference may be attributed to the 
different assay conditions used for testing whole vector (overnight) vs. hexon 
peptides (6 hrs), or could reflect different levels of antigenic stimulation. 
 In contrast to hexon-specific CD4+ T-cells, perforin, TNFα, and MIP1α 
dominated the hexon-specific CD8+ T-cell responses, and IL-2 and IFN-γ 
tended to be lower.  The overall level of functionality in the hexon-specific 
CD8+ T-cell response tended to be higher than the CD4+ hexon-specific 
response, with the majority of CD8+ T-cells responding with at least two 
functions (Figure 11A, bottom).  Similar to whole Ad vector responses, hexon-  
specific CD8+ T-cells were highly skewed towards effector like activity, with 
perforin clearly dominating the entire response.  With the exception of  
monofunctional responses, perforin was present in combination with another 
function in nearly every hexon-specific CD8+ T-cell (Figure 11B, bottom). 
There was no apparent difference in functionality between hexon-specific 
CD8+ T-cell responses directed against conserved or variable regions. 
 
Cross-serotype reactivity of Ad-specific T cells in humans 
 To test the ability of Ad-specific T-cells to cross-react with disparate Ad 
serotypes, we examined T-cell responses against the chimpanzee-derived 
adenoviruses AdC6 and AdC7, which humans are rarely seropositive for.  In 
all subjects examined CD4+ T-cells responded to Ad5, AdC,6 and AdC7, 
demonstrating a high level of cross-serotype reactivity.  The predominant  
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Figure 12: Ad-specific T-cells are cross reactive. Cross reactivity of Ad-specific 
T-cells was measured in seventeen healthy donors by stimulating PBMCs overnight with 
human adenovirus 5 (Ad5), chimpanzee 6 (AdC6) and chimpanzee 7 (AdC7) followed by 
intracellular cytokine staining. A) The total percentage of Ad5, AdC6 and AdC7 CD4+ (top 
row) and CD8+ (bottom row) T-cells. Ad-specific cells stained positive for IL-2, IFN-γ, MIP1α, 
Perforin and or TNF-α. B) Percentage of Ad-specific cells with a polyfunctional response. 
Pies represent all responding Ad-specific cells making IL-2, IFN-γ, MIP1α, Perforin and or 
TNFα following stimulation with Ad5, AdC6, or AdC7 vector. Each slice represents the 
proportion of the cells producing four of five cytokines (blue), three of five (green), two of five 
(yellow) and one of five (orange).  C) Percentage of Ad-specific cells with a polyfunctional 
response. Bars represent the percentage of CD4+ (top) and CD8+ (bottom) T-cells making 
each combination of IL-2, IFN- γ, MIP1α, Perforin and or TNFα following stimulation with Ad5 
(black) AdC6 (pink) and AdC7 (purple) vector. Plus signs represent cells staining positive (+) 
for each cytokine. 
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functional response differed between the vectors, with Ad5 and AdC7 
inducing mainly IFN-γ, while AdC6 induced primarily TNFα (Figure 12A). 
Despite these differences, the overall functionality of the Ad-specific CD4+  
T-cell response was quite similar between all three vectors (Figure 12B, C). 
The CD4+ T cell response to AdC6 was significantly larger than to Ad5 
(p<0.01). Cross-serotype reactive Ad-specific CD8+ T-cells were also present 
in every donor, with no differences in magnitude and a similar degree of 
functionality (Figure 12B, C). There was no significant difference in the total 
magnitude of the CD8+ T-cell response to Ad5, AdC6 and AdC7, and the 
functional profiles of cross-reactive Ad-specific CD8+ T-cells were also similar. 
Discussion 
 Ad vectors are commonly used to deliver transgenes in gene therapy 
and vaccination.  It is well known that Ad-specific neutralizing antibodies can 
limit the effectiveness of Ad-based vectors; however the potential role of Ad-
specific T-cells to further curtail Ad vector efficacy is unclear.  Here we 
provide a minimal estimate of the level of Ad-specific T-cell responses in 
humans.  We find that Ad-specific T-cell responses are universal, as every 
subject we tested had a detectable CD4+ and CD8+ T-cell response against 
Ad5, despite a seroprevalence of only 40% in the United States. 
 Our findings indicate that Ad-specific T-cells are readily detectable 
using replication defective Ad particles or Ad hexon peptides.  Although the 
response magnitude against each particular stimulant may vary between 
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subjects, both CD4+ and CD8+ T-cells responded in a similar fashion.  
Interestingly, Ad-specific T-cells appear to be maintained continually in an 
effector-like state, particularly Ad-specific CD8+ T-cells.  Unlike our 
observations for common human viral pathogens, including cytomegalovirus, 
Epstein-Barr virus, and Influenza, Ad-specific CD8+ T-cells are highly prone to 
effector function upon stimulation [166].  This is further manifested in the 
effector-like memory phenotype maintained by a substantial proportion of the 
Ad-specific CD8+ T-cell response.  Due to extensive sequence homology 
between various human Ad serotypes, Ad-specific T-cells in part cross-react 
and are likely repeatedly stimulated by periodic infections with different Ad 
serotypes [116,118,161].  As a result, human Ad-specific CD8+ T-cells are 
unlikely to be restricted specifically to a single Ad serotype, and able to 
recognize not only targets infected with virus homologous to the vector used 
for expansion but also heterologous virus from diverse serotypes. This high 
level of cross-reactivity very likely leads to the continual maintenance of Ad-
specific CD8+ T-cells in an effector-like state, as humans are expected to be 
repeatedly infected with different serotypes of Ad. Furthermore, Ad viruses 
persist in lymphatic tissues and if they remain transcriptionally active this 
would further maintain T-cells at an activated state [71].  
 One reason for the divergence between Ad serostatus and Ad 
responsive T-cells is the presence of common T-cell epitopes in conserved 
regions of the Ad hexon protein, which accounts for ~80% of the entire hexon 
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sequence.  Similar to previous findings obtained with CD4+ and CD8+ T-cell 
lines, we find that both CD4+ and CD8+ T-cell responses can be detected 
against the conserved and variable hexon peptide pools.  Conservation of  
T-cell epitopes in hexon leads to cross-reactivity even among divergent 
serotypes from chimpanzees, AdC6 and AdC7. Because of this high degree 
of cross-reactivity, it is impossible to know whether, for example, Ad5-reactive 
T-cells are truly Ad5-specific and generated from natural Ad5 infection, or 
simply cross-reacting with Ad5 following infection with another Ad serotype. 
Finally, due to this extensive cross-reactivity, it is likely that transgene 
product-specific immune responses induced by Ad vectors derived from rare 
human serotypes, which are currently under development, may still be 
affected by Ad-specific cytotoxic T-cells capable of recognizing Ad vector 
transduced cells.   
 
Material and Methods 
T-cell Responses 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from 
aphaeresis of adult healthy donors by the University of Pennsylvania Center 
for AIDS Research Immunology Core. T-cell responses to Ad5, AdC6 and 
AdC7 were measured by flow cytometry following whole vector and peptide 
stimulation. Samples were analyzed on a modified LSR II flow cytometer (BD 
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Immunocytometry Systems, San Jose, CA). Data analysis was performed 
using FlowJo 8.7 (TreeStar, San Carlos, CA). 
 
Statistics 
Variability in the assays was tested using Levene’s robust variance test 
with Brown and Forsythe’s 10% trimmed mean alternative.. Analyses were 
conducted using Stata MP 10.0.  The T-cell response to different vectors and 
peptide pools were compared using a Friedman Statistic. When two groups 
were compared a Wilcoxon's sum rank test, a non-parametric t-test, was 
used.  
 
Portions of this work have been previously published: Hutnick NA, Carnathan 
DG, Demers K, Makedonas G, Ertl HC, Betts MR. “Adenovirus-Specific 
Human T cells are Pervasive, Polyfunctional, and Cross Reactive.” Vaccine. 
2010 Feb 23; 28(8):1932-41 
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Chapter 4: Baseline Ad5 serostatus does not 
predict Ad5-HIV vaccine-induced expansion of 
Ad-specific CD4+ T-cells 
 
Abstract 
The mechanisms underlying possible increased HIV-1 acquisition in 
adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors 
in the Merck STEP trial remain unclear. One hypothesis for these results is 
pre-existing Ad5-specific CD4+ T-cells in Ad5-seropositive subjects became 
activated upon vaccination, making them the optimal targets for HIV infection 
and replication. To examine this hypothesis, we studied Ad5-specific CD4+  
T-cell responses in the Merck phase I Ad5 gag/pol/nef safety study testing the 
same vector, dosing and schedule used during the STEP study. We find Ad5 
serostatus does not predict Ad5-specific CD4+ T-cell frequency, and Ad5-
specific CD4+ T-cells were present in over 90% of subjects. No significant 
differences in the magnitude or functionality of Ad5-specific CD4+ T-cells 
between Ad5-seropositive and Ad5-seronegative subjects were observed 
following vaccination. Vaccination did not affect the activation or mucosal 
homing receptor expression of Ad5-specific CD4+ T-cells in either serogroups. 
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These findings indicate no causative role for Ad5-specific CD4+ T-cells in 
increasing HIV-1 susceptibility in Ad5-seropositive STEP trial subjects. 
Introduction 
Given the urgent need for an effective HIV vaccine, it is of paramount 
importance to gain further insight into the reasons underlying the failure of the 
Merck STEP HIV vaccine trial.  Post-hoc analysis of the STEP trial showed 
vaccination with an adenovirus 5 (Ad5) vector based HIV-1 vaccine increased 
HIV-1 acquisition rates in volunteers with an adenovirus 5 neutralizing 
antibody (nAb) titer greater than 200 [83]. It has been proposed that the Ad5 
vector caused activation and expansion of pre-existing Ad5-specific CD4+  
T-cells in vaccinees with high neutralizing antibody titers to Ad5 prior to 
vaccination.  Activated Ad5-specific CD4+ T-cells then served as  targets for 
HIV infection [167].  However, neither the prevalence of Ad5-specific CD4+  
T-cells in humans, nor their relationship with Ad5 neutralizing antibody titer 
has been characterized.  Moreover, it is unknown to what degree vaccination 
with Ad5 vectors stimulates pre-existing Ad5-specific CD4+ T cells in vivo .  It 
is not possible to adequately addressing these questions for the STEP trial as  
blood samples were not collected before vaccination and at only two time 
points, weeks 8 and 30, after vaccination [81]. 
To test if Ad5-specific CD4+ T-cells may have increased the vaccinee’s 
susceptibility to HIV-1 infection, we analyzed samples from subjects enrolled 
in Merck phase I HIV vaccine trials that utilized similar or identical Ad5 
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vectors to those used in the STEP trial at various dosing regimens.  As pre-
vaccination samples were available for each subject, we could precisely 
determine relationships between pre-existing Ad5-specific CD4+ T-cell 
responses and Ad5 nAb titers, and measure the longitudinal effect of 
vaccination on frequencies, phenotypes, and functionalities of Ad5-specific 
CD4+ T-cells.   Our results show that Ad5-specific CD4+ T-cells are nearly 
universally present in subjects and do not correlate with Ad5 nAb titer. Ad5-
specific CD4+ T-cells are only expanded following vaccination in subjects 
receiving the highest Ad5 vector dose, 3x1010 vp, the same dose used for the 
STEP trial. However, it is unlikely Ad5-specific CD4+ T-cells were responsible 
for the increased acquisition of HIV observed in the STEP trial, as there were 
no significant differences in the magnitude, activation, or mucosal homing of 
Ad5-specific CD4+ T-cells in Ad5-seronegative and Ad5-seropositive subjects.  
 
Results 
Ad5 nAb titers and T-cell responses were tested in samples from 
seven cohorts that received various Ad5 HIV vaccines in Merck phase I trials 
(Table 3).   To test for Ad-specific T-cell responses we developed a sensitive 
and reproducible polychromatic intracellular cytokine-staining assay using 
replication-defective Ad5 particles for stimulation (Chapter 3, Figure 1A, 1C).   
Stimulating cells with the entire Ad5 vector allows for the detection of T-cells  
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Table 3: Merck Ad5 Vaccine Subjects 
Group Number of 
Subjects 
Vaccine Schedule Baseline 
Neutralizing 
Antibody titer 
Placebo 5 Placebo (AIPO4) Weeks 0, 4, 26 18-2598 
A 6 Placebo (AIPO4) weeks 0,4,8, 
1x1010Ad5gag week 26 
≤18-58 
B 5 5mg gag DNA/AlPO4 weeks 0, 4, 8 
1x1010vp Ad5 gag week 26 
≤18-278 
C 5 Ad5 gag 1x1010,  weeks 0, 4, 26 ≤18-1047 
D 5 HIV-1 gag MRK Ad5 1x109 vp at 
weeks 0, 4, 26 
≤18-1146 
Seronegative 
(016 trial) 
5 MRKAd5HIV-1gag/pol/nef, 3 x1010, at 
weeks 0 followed weeks 0-78  
≤18 
Seronegative 
(016 trial) 
5 MRKAd5HIV-1gag/pol/nef, 3 x1010, at 
WKS 0,4,26   
≤18 
Seropositive 
(016 trial) 
5 MRKAd5HIV-1gag/pol/nef, 3 x1010, at 
weeks 0, 4, 26   
203-442 
Table 3: Merck Ad5 HIV vaccine subject groups.  
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recognizing Ad5 epitopes from the entire vector as opposed to using 
overlapping peptides for a single protein such as hexon only.  
To characterize the relationship between Ad5 nAb titers and Ad5-
specific CD4+ T-cell responses, we analyzed samples from 40 subjects with 
varying Ad5 nAb titers who were enrolled in various Ad5 HIV vaccine trials. Of  
these subjects, 15 (five seronegative weeks 0-4, five seronegative weeks 0-
78, and five seropositive weeks 0-78) were enrolled in the Merck 016 phase I 
HIV-1 vaccine safety trial and received Ad5 vectors used in the STEP trial at 
weeks 0, 4, and 26 [80]. All subjects independent of vaccination group were 
combined at baseline based on Ad5 serostatus (seronegative Ad5 nAb ≤18, 
seropositive Ad5 nAb >18). We detected similar frequencies of Ad5-specific 
CD4+ T-cells with a frequency of 0.05% to 2.0% in > 80% of Ad5-seropositive 
and Ad5-seronegative subjects at baseline (Figure 13A). Within Ad5-
seropositive subjects, Ad5-specific CD4+ T-cell frequencies did not correlate 
with Ad5 nAb titers  (Figure 13B). Though nAbs are serogroup-specific, Ad -
reactive CD4+ T-cells cross-react due to extensive sequence homology 
between the 51 human serotypes, accounting for the universal presence of 
Ad5-reactive CD4+ T-cell despite a seroprevalence of only 40% 
[32,116,117,118,161].  
Following vaccination, there were no increases in the percentage of 
Ad5-specific CD4+ T-cells in groups A-D. Subjects in these groups received a 
lower dose of Ad5 vector, and in some cases only one vector injection in  
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Figure 13: Ad5-specific CD4+ T-cell frequency does not correlate with 
Ad5 neutralizing antibody titer. Forty total subjects with a range of Ad5 nAb titers 
were analyzed (A,B). Ten Ad5-seronegative (five assessed weeks 0-4, five assessed weeks 
0-78, gray symbols) and five Ad5-seropositive subjects (black symbols) received 3x1010 vp 
Merck Ad5 gag/pol/nef at weeks 0, 4 and 26 (C, D, E). Ad-specific CD4+ T-cells represents 
the percentage of cells producing IFN-γ, IL-2, MIP1α, TNFα, and/or perforin production in 
response to Ad5 virus particle stimulation. A) Similar Ad5-specific CD4+ T-cell magnitude 
regardless of baseline Ad5 serostatus. B) No correlation between total Ad5-specific CD4+ T-
cell magnitude and Ad5 nAb titer. C) Ad5 nAbs titers increase in Ad5-seronegative subjects 
after one vaccination (P  < 0.05). D) Ad5 nAb titers remain elevated in baseline Ad5-
seronegative subjects throughout the vaccine course (gray asterisk, P < 0.05, weeks 4-78). 
E) Ad5-specific CD4+ T-cell frequency increases after vaccination in Ad5-seropositive 
subjects (open boxes, black asterisk) at weeks 4 (P < 0.002) and 8 (P < 0.03) and Ad5-
seronegative subjects (grey boxes, gray asterisk) at week 4 (P < 0.02).  Plots depict the 
median, 25th and 75th percentile (box plots) and the minimum and maximum values 
(whiskers). Triangles indicate vaccination time points. 
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contrast to the three doses of 3x1010 vp used in the seropositive and 
seronegative 016 subjects and STEP trial. Though Ad5-specific CD4+ T-cells 
were prevalent, this data suggests they require a high dose of vector to 
become activated by vaccination. Because there were no significant 
differences in Ad5-specific CD4+ T-cells observed in groups A-D or the 
placebos, the remainder of our analysis will focus on the seronegative and 
seropositive 016 trial subjects only. 
Four weeks after the first Ad5-HIV-1 vector administration in the fifteen 
016 trial vaccinated subjects, Ad5 nAb titers in baseline Ad5-seronegative 
subjects (n = ten) increased (P < 0.05), becoming comparable to those seen 
in baseline Ad5-seropositive subjects (n = five) in all but one individual (Figure 
13c) who seroconverted by week 8 (Figure 13D). Ad5-specific CD4+ T-cells 
increased in both groups (P < 0.002, baseline seropositive; P < 0.03, baseline 
seronegative) after the initial vector dose (Figure 13E, Figure 14). Successive 
vaccinations further expanded Ad5-specific T-cells in some subjects, but 
these responses were transient in most individuals (Figure 13E, Figure 15).  
At no point was there a statistical difference between the serogroups. 
Having found no differences between the serogroups in the magnitude 
or expansion of total Ad5-specific CD4+ T-cells, we next examined the 
relationship between Ad5 serostatus and potential functional differences in 
Ad5-specific CD4+ T-cells before and after vaccination.  Ad5-specific CD4+ T-  
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Figure 14: Ad5-specific T-cell responses following a single vaccination. 
Ad5-seronegative subjects (n = ten, grey) and Ad5-seropositive subjects (n = five, black) 
received 3x1010 vp Merck Ad5 gag/pol/nef at week 0. We measured the percentage of 
cytokine+ CD4+ T-cells by intracellular flow cytometry and all results are background 
subtracted. In both groups, total responses were elevated at week 4 compared to baseline (P  
< 0.002, baseline seropositive; P < 0.03, baseline seronegative).  In Ad5-seropositive 
subjects the percentage of Ad-specific CD4+ T-cells expressing IFN-γ (P  < 0.002), IL-2 (P  < 
0.002), MIP1α (P < 0.03), and TNFα (P < 0.0001) were significantly increased at week 4, 
while the percentage of Ad-specific CD4+ T-cells expressing IFN-γ (P  < 0.03), MIP1α (P  < 
0.01), and perforin (P  < 0.001) were significantly increased above baseline in Ad5-
seronegative subjects at week 4. 
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Figure 15: Change in the percentage of Ad5-specific CD4+ T-cells. Ten 
Ad5-seronegative (Ad5 nAb titer ≤18, five subjects weeks 0-4 and five subjects weeks 0-78, 
grey) and five Ad5-seropositive subjects (Ad5 nAb titer > 18, weeks 0-78, black) received 
3x1010 vp Merck Ad5 gag/pol/nef at weeks 0, 4 and 26 with PBMCs collected at weeks 0, 4, 
8, 18, 26, 30, 42, 52 and 78. We measured the percentage of CD4+ IFN-γ IL-2, MIP1α, 
TNFαandperforin positive T-cells by intracellular flow cytometry. Ad5-specific CD4+IFN-γ T-
cell frequency increases after vaccination in Ad5-seropositive subjects at weeks 4 (black 
asterisks, P  < 0.005), 8 (P  < 0.05) and 30 (P  < 0.5) and Ad5-seronegative subjects at week 
4 (grey asterisks, P  < 0.03). In Ad5-seropositive subjects the percent of Ad-specific CD4+ T-
cells producing IL-2 increased above baseline at week 4 (P  < 0.03), MIP1α at week 4 (P  < 
0.03), and TNFα at weeks 4 (P  < 0.0001) and 8 (P  < 0.005); in Ad5-seronegative subjects 
the percent of Ad-specific CD4+ T-cells producing MIP1α increased above baseline at weeks 
4 (P  < 0.005) and 42 (P  < 0.001), and perforin at weeks 4 (P  < 0.001), 42 (P  < 0.0001), 52 
(P  < 0.05) and 78 (P  < 0.05). 
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cells that produced IFN-γ, IL-2, MIP-1α, TNF-α, and/or perforin were present 
at baseline in most individuals at similar frequency regardless of Ad5 
serostatus (Figure 16A).  There was no correlations between Ad5 nAb titer 
and the percentage of Ad5-specific CD4+ T-cells that produced any one or 
more functions (data not shown).  IFN-γ dominated the response in both 
serogroups, but accounted for only ~50% of the total response (Figure 16B). 
Measuring IFN-γ alone by intracellular staining or ELISpot would 
underestimate the magnitude of the response. Approximately 20% of 
responding CD4+ cells also produced the effector functions MIP1α and 
perforin regardless of serostatus. 
After the first vaccination Ad5-specific CD4+IFN-γ+ and MIP1α+ T-cells 
increased in both groups (P < 0.05), with no differences in the fold change 
between serogroups (Figure 14, Figure 16C). Seropositive subjects had an 
early expansion of memory-like cells. The frequency of Ad5-specific CD4+ T-
cell producing IL-2 (P < 0.03) and TNFα (P < 0.001) increased in Ad5-
seropositive subjects only and accounted for a higher proportion of the total 
response (P < 0.05) compared with seronegative subjects (Figure 14, Figure 
15, Figure 16C-D). In contrast to these early responses, Ad5-seronegative 
subjects had a later more effector-like expansion of Ad5-specific CD4+ T-
cells. In seronegative subjects, the effector functions perforin and MIP1α were 
increased above baseline following the third vector dose.  (Figure 15, Figure 
16D). Despite these transient increases in CD4+ T-cell functions within  
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Figure 16: CD4+ functionality does not differ with baseline serostatus. IL-
2 (2, downward triangle), IFN-γ (G, circle), MIP1α (M, diamond), perforin (P, square) and 
TNFα (T, upward triangle) production in response to Ad5 virus were measured by intracellular 
cytokine staining. For all panels, gray symbols, lines, or box plots depict baseline Ad5- 
seronegative subjects, and open black symbols, lines, or box plots depict baseline Ad5- 
seropositive subjects.  A) Percentage of baseline Ad5-specific CD4+ T-cells producing various 
responses separated by Ad5 serostatus. Bars represent the mean ± SEM. B) Percent 
contribution of Ad5-specific CD4+ T-cells making each respective function to the total Ad5-
specific CD4+ T-cell response at baseline. C) The fold change in each Ad-specific CD4+ T-cell 
function after a single vaccination. The fold change in IL-2 was significantly higher in Ad5- 
seropositive subjects at week 4 (P  < 0.02). D) Transient changes in Ad-specific CD4+ T-cell 
function after vaccination. In Ad5-seropositive subjects IFN-γ increased from baseline (black 
asterisk) at week 4 (P < 0.005), 8 (P < 0.05) and 30 (P < 0.5), IL-2 at week 4 (P  < 0.03), 
MIP1α at week 4 (P  < 0.03), and TNFα at weeks 4 (P  < 0.0001) and 8 (P  < 0.005); in Ad5-
seronegative subjects, IFN-γ increased (gray asterisk) above baseline at week 4 (P < 0.03), 
MIP1a at weeks 4 (P  < 0.005) and 42 (P  < 0.001), and perforin at weeks 4 (P  < 0.001), 42 
(P  < 0.0001), 52 (P  < 0.05) and 78 (P  < 0.05). Plots depict the median, 25th and 75th 
percentile (boxes) and the minimum and maximum values (whiskers). Triangles indicate 
vaccination time points. 
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Figure 17: Polyfunctionality of Ad5-specific CD4+ responses in 
vaccinated subjects. We stimulated PBMCs with whole Ad5 vector and cytokine 
responses were measured by intracellular cytokine staining.  The percentage of cells making 
each possible combination of cytokines was calculated using the Boolean function in FlowJo. 
Bars represent the average percentage of responding Ad5-specific CD4+ T-cells making each 
cytokine combination at each time point. Ad5-Seronegative subjects demonstrated similar 
polyfunctionality at all time points compared with Ad5-seropositive subjects. 
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serogroups, there was never a significant difference between the groups for 
the percentage of Ad5-specific CD4+ T-cells producing IFN-γ, IL-2, MIP1α, 
TNFα, or perforin. The degree of polyfunctionality of Ad5-specific CD4+ T-cells 
remained comparable between baseline Ad5-seronegative and Ad5-
seropositive subjects and vaccination did not alter the polyfunctional profile of 
the CD4+ T-cell response (Figure 17). No difference was found in Ki-67 
expression for total (data not shown) or Ad5-specific CD4+ T-cells (Figure 
18A-B) between the serogroups or compared to baseline.   
Expression of the mucosal trafficking-associated markers α4 and β7 did 
not differ significantly from baseline within either serogroup on total memory 
(TM: all CD45RO+ and CCR7-CD45RO–) and effector memory (TEM: CCR7–
CD45RO+) CD4+ T-cells (Figure 18D first graph) or Ad5-specific TM or TEM 
CD4+ T-cells (Figure 18C, Figure 18D second graph) after vaccination. 
Moreover, Ad5-specific CD4+ TM and TEM cells represented a small fraction of 
total circulating α4+ β7+CD4+ T-cells, and did not change significantly after 
vaccination (Figure 18D third graph). Thus, while transient changes in the 
phenotype and magnitude of Ad5-specific CD4+ T-cell responses were 
detected within groups after vaccination, no significant differences between 
groups were observed.   
 
Ad-specific CD4+ T cells at baseline are capable of expressing markers 
indicative of central memory-like (CD27+CD45RO+CD57-), effector memory 
(CD27-CD45RO+CD57-), and effector cells (CD27+CD45RO+CD57+/-) 
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Figure 18: Representative flow plots of Ki67 and α4/β7 staining.  Data 
shown have been gated on CD3+ CD4+ T-cells. Grey density plots represent total memory 
CD4+ T-cells.  Red dot overlays represent Ad-specific CD4+ T-cells as defined by production 
of one or more cytokine A) Ki67 staining in total (grey) and Ad-specific (red) CD4+ T-cells in a 
representative donor. B) Average percentage of Ad-specific Ki67+ CD4+ T-cells. C) 
representative staining on α4 and β7 expression on total (grey) and Ad-specific (red) CD4+ T-
cells. D) Percentage of total (left) and Ad5-specific (center) α4+β7+CD4+T-cells. Percentage of 
α4
+
β7
+CD4+T-cells that are Ad5-specific (right). 
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Figure 19: Ad-specific T-cells expanded by vaccination have an effector 
and central memory-like phenotype. Surface staining and analysis by flow 
cytometry was used to determine the phenotype of cytokine producing Ad-specific CD4+ T-
cells in previously described subjects. Effector cells are defined as CD27-CD45RO-, effector 
memory as CD27-CD45RO+ and central memory-like as CD27+CD45RO+. Cells making IFN-
γ, IL-2, TNFα, MIP1α and or perforin following vaccination are in red and all CD4+ T cells are 
in grey. A) The phenotype of Ad5-specific CD4+ T-cells at baseline in representative subjects. 
B) The phenotype of cytokine producing cells for a representative subject at week 4. C) The 
phenotype of ad-specific cells following vaccination in a representative subject.  
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(Figure 19A; CD57 data not shown).   The presence of each memory 
phenotype varies between subjects likely based on the frequency, time, and 
serotype of natural Ad exposure. Despite variations in the magnitude of a 
given phenotype, the functionality of a given phenotype remained relatively 
constant. For example, in the representative donor shown, week 4 effector 
cells made predominantly perforin, whereas central memory-like cells 
produced predominantly IL-2 and TNFa and effector memory cells produced 
all 5 cytokines (Figure 19B). Following vaccination, there was an expansion of 
Ad-specific cells with all phenotypes but no alterations in the percentage of 
the response with a given phenotype in either Ad5-seropositive or Ad5-
seronegative subjects (Figure 19C). 
Discussion 
Here, we examined Ad-specific CD4+ T-cell responses before and after 
vaccination to determine their potential role in enhancing susceptibility to  
HIV-1 acquisition.  We tested subjects from several Merck phase I trials that 
received Ad5 vectors, including subjects from the 016 trial, that used the 
same product, dosage, and regimen as was used in the STEP trial.  Most 
importantly, our studies include baseline samples for each subject, thus 
permitting precise characterization of changes in the Ad5-specific CD4+  
T-cell response to vaccination. Such samples were not collected in the STEP 
trial; which made it impossible to assess the actual effect of Ad5 vector 
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administration on Ad5-specific CD4+ T-cells and their potential role in 
enhancing susceptibility to HIV-1 acquisition.  
One hypothesis for why an increased risk of HIV infection occurred in 
vaccinated seropositive subjects was pre-existing Ad5-specific CD4+ T-cells 
were activated by vaccination making them the optimal targets for HIV 
infection. Our results indicate that Ad5-specific CD4+ T-cell responses 
induced by Ad5 vector administration likely did not play a role in increasing 
susceptibility to HIV infection.   Three findings support this conclusion:  first, 
we found no correlation between Ad5 nAb titers and the presence or 
magnitude of Ad5-specific CD4+ T-cell responses prior to vaccination.   Thus, 
high Ad5 nAb titers do not predict frequencies of Ad5-specific CD4+  
T-cells.  Second, Ad5-specific T-cells within subjects who are Ad5 nAb 
seronegative at baseline expand similarly to Ad5 nAb seropositive subjects in 
response to Ad5 vector administration.  There were also no differences 
between the serogroups in the level of activation as measured by Ki67, or 
mucosal homing as measured by α4β7.  However, enhanced susceptibility to 
infection was not found within STEP trial participants with low or absent Ad5 
nAb titers at baseline.  Third, after vaccination, Ad5 nAb seronegative 
subjects uniformly become Ad5 nAb seropositive, yet again no enhanced 
susceptibility was noted in baseline Ad5-seronegative STEP participants after 
receiving multiple doses of the Ad5 vector.  
Taken together, these data suggest that any linkage between Ad5- 
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serostatus and Ad5-specific T-cell-related increase in HIV-1 acquisition 
should only have been observed early after the first vaccine dose, for 
afterwards Ad5-specific T-cell responses in baseline Ad5-seronegative 
subjects appear immunologically equivalent to baseline Ad5-seropositive 
subjects. With the caveat that our analyses are restricted to circulating CD4+ 
T-cells and did not address potential differences in activated Ad5-specific 
CD4+ T-cells within mucosal tissues after vaccination, our results do not 
support the hypothesis that Ad5-specific CD4+ T-cells contributed to the 
potential increased HIV-1 acquisition in the STEP trial.  
 
Materials and Methods 
 
T-cell Responses 
Frozen PBMCs were obtained from participants in 5 Merck phase I HIV 
Ad5 trials (Table 3). The vaccination dose and schedule used for the 
seropositive and seronegative subjects was identical to that used in the phase 
II STEP trial. T-cell responses were by stimulating PBMCs over night with 
whole replication-defective Ad5 vector. Cells were analyzed on a modified 
LSR II flow cytometer (BD Immunocytometry Systems, San Jose, CA). Data 
analysis was performed using FlowJo 8.7 (TreeStar, San Carlos, CA). Ad5 
neutralizing antibody titers were measured as previously described [163]. 
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Statistics  
To test for group differences over time we performed mixed effects 
models. Mixed effects models are similar to regression models except they 
account for the inherent correlation between measurements from the same 
subject and allow us to use all available measurements over time. For 
comparisons between baseline and subsequent time points within each group 
we also used mixed effects models. Time was considered to be a discrete 
variable, lessening the power of these tests compared to tests where time is a 
continuous variable. Correlations between Ad5 nAb titers and T-cell functions 
were computed at baseline using Spearman correlations. Correlations over 
the entire time period were computed using partial correlation coefficients 
controlling for individual subject effects in the repeated measurements. All 
data was log-transformed using base e. 
 
Portions of this work have been previously published: Hutnick NA, Carnathan 
DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson 
MN, Casimiro DR, Ertl HC, Betts MR. “Baseline Ad5 serostatus does not 
predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T 
cells.” Nature Medicine. 2009. 15(8), 876. 
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Chapter 5: Vaccination with Adenovirus 5 HIV-1 
vector differentially expands Ad5-specific CD8+ 
T-cells in seropositive and seronegative 
subjects 
 
Abstract 
Adenoviral (Ad) vaccine vectors represent both a vehicle to present a 
novel antigen to the immune system as well as restimulate immune 
responses against the Ad vector itself.  To what degree Ad-specific CD8+  
T-cells are restimulated by Ad-vector vaccination is unclear, although such 
knowledge would be important as vector-specific CD8+ T-cell expansion could 
potentially limit Ad vaccine efficacy further beyond Ad-specific nAb alone.  
Here we address this issue by measuring human Ad5-specific CD8+ T-cells in 
recipients of the Merck Ad5 HIV-1 vaccine vector before, during, and after 
vaccination by multicolor flow cytometry.  Ad5-specific CD8+ T-cells were 
detectable in 95% of subjects prior to vaccination, and displayed primarily an 
effector-type functional profile and phenotype.  Peripheral blood Ad5-specific 
CD8+ T-cell numbers expanded after Ad5-HIV vaccination in all subjects, but 
differential expansion kinetics were noted in some baseline Ad5 nAb 
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seronegative subjects compared to baseline Ad5 nAb seropositive subjects. 
However, in neither group did vaccination alter polyfunctionality, mucosal 
targeting marker expression, or memory phenotype of Ad5-specific CD8+ T-
cells.  These data indicate that repeat Ad5-vector administration in humans 
expands Ad5-specific CD8+ T-cells without overtly affecting their functional 
capacity or phenotypic properties.  
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Introduction 
Vectors based on the human Ad5 are currently leading candidates for 
vaccines designed to elicit cellular immunity. Studies both in animals and 
humans have demonstrated that Ad5 vectors are capable of inducing potent 
and sustained transgene product-specific CD4+ and CD8+ T-cell responses 
[74,76,113]. Additionally, these vectors have been generally safe and well 
tolerated [80,170,171]. However, one major hurdle to Ad-vector based 
vaccines is the presence of pre-existing Ad-specific immunity. 
  Most studies of pre-existing Ad-specific immunity have focused on 
neutralizing antibodies (nAb). In animals and humans, Ad5 vaccination is less 
effective if there are pre-existing Ad5-specific nAbs [112,113]. Similarly, pre-
exposure to Ad5 vector reduces the efficacy of subsequent booster 
vaccinations, thereby limiting the ability for homologous vector boosting [115].  
The prevalence of nAbs to Ad5 varies worldwide, with up to 50% of adults in 
the United States and as many as 90% of adults in Africa testing seropositive 
[31]. To overcome this limitation, rare Ad serotypes with low seroprevalence 
have been developed as vaccine vectors [17,56,172].   
Ad-specific CD4+ and CD8+ T-cell responses have also been detected 
in humans [59,117]. However, their magnitude, functional properties, and 
phenotypic characterization directly ex vivo are not well described. Ad-specific 
T-cells are likely more prevalent in humans than Ad serotype-specific nAbs 
due to cross-reactivity of T-cells against conserved viral sequences, unlike 
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nAbs that are predominantly directed to the hypervariable outer loops of the 
Ad hexon. Indeed it has been demonstrated that ex vivo generated human 
CTL lines are capable of killing target cells infected with Ad serotypes from 
multiple subgroups [116].  Though Ad-specific T-cells have been identified 
following natural infection, it is unclear whether Ad-specific T-cells stimulated 
by vaccination are similar to those induced by natural infection.  Moreover, 
the effect of repeat homologous E1-deleted Ad5 vector administration upon 
pre-existing Ad5-specific CD8+ T cells has not been assessed in human 
vaccine recipients. 
 To assess the effect of Ad vector administration on the Ad-specific 
CD8+ T-cell response in humans, we analyzed peripheral blood mononuclear 
cells (PBMCs) from subjects enrolled in a Phase 1 Ad5-vector HIV vaccine 
trial. Using a whole Ad5 vector stimulation together with polyfunctional flow 
cytometry, we defined the prevalence, magnitude, functionality and 
phenotype of Ad5-specific CD8+ T-cells before and after Ad5 vector 
administration. Our results demonstrate that while Ad5-specific CD8+ T-cells 
are present in most humans and transiently expand after vaccination, they do 
not change in either phenotype or function.  
 
Results 
 To assess the total magnitude, functionality, and phenotypes of Ad5-
specific CD8+ T-cells, we stimulated human PBMCs with Ad5 vector and  
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Figure 20: Baseline CD8+ T-cell responses. Forty total subjects with a range of 
Ad5 nAb titers were analyzed. Five Ad5-seronegative (Ad5 nAb titer ≤18, gray symbols) and 
five Ad5-seropositive subjects (Ad5 nAb titer >18, black symbols and white boxes) received 
Merck Ad5 gag/pol/nef as described in Methods. Box plots represent 25th-75th percentile with 
lines being the 10-90% range. outliers are shown as dots. CD8+ T-cell responses were 
measured by flow cytometry following whole Ad5 vector stimulation. A) Gating strategy for 
measuring Ad5-specific T-cells by intracellular cytokine staining. At least 100,000 PBMCs 
were collected on a modified LSR II.  Singlets were selected with a FSC-A and FSC-H, 
followed by a lymphocytes gate, dead cell exclusion, and exclusion of contaminating CD14+ 
monocytes and CD19+ B-cells. CD3+ T-cells were selected and then CD8+ cells by 
CD8+CD4+. Central memory, effector memory and effector CD8+ T cells were selected before 
gating on each cytokine. Because cells can store perforin and these appear perforin+, Ad5-
specific CD8+perforin+ T cells must also be positive for another function to be considered as a 
responding event. B) Total Ad5-specific CD8+ response. The total Ad5-specific CD8+ 
response was computed by summing cells making at least IL-2, IFN-γ, MIP1α, or TNFα as 
measured by flow cytometry. C) There was no difference in the magnitude of the Ad-specific 
CD8+ T-cell response between serogroups at baseline. D) There was no correlation between 
the magnitude of Ad5-specific CD8+ T-cell responses and nAb titer at baseline. E) There was 
a correlation between the magnitude of Ad5-specific CD4+ and Ad5-specific CD8+ T-cell 
responses at baseline.  
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measured CD8+ T-cell responses by polychromatic flow cytometry (Figure 
20A).  We detected Ad5-specific CD8+ T-cell responses in 95% of all donors 
at the week 0 baseline (Figure 20B). There was no difference in frequencies 
of Ad5-specific CD8+ T-cells between baseline seropositive and seronegative 
subjects (Figure 20C, p>0.05).  Likewise, there was no correlation between 
frequencies of Ad5-specific CD8+ T-cells and the Ad5 nAb titer at baseline 
(Figure 20D, p>0.05). There was however a positive correlation between 
frequencies of baseline Ad5-specific CD4+ and CD8+ T-cells (Figure 20E).  
 
Vector induced CD8+ T-cell expansion 
 We next examined the effect of Ad5 vector administration on the pre-
existing Ad5-specific CD8+ T-cell response. After the initial vaccine 
administration, frequencies of Ad5-specific CD8+ T-cells in the blood 
increased significantly above pre-vaccination frequencies in baseline Ad5-
seropositive (p<0.0001) but not in baseline Ad5-seronegative subjects as a 
group (Figure 21A). On an individual basis, frequencies of Ad5-specific CD8+ 
T-cells increased in three of five seronegative subjects following the initial 
dose (data not shown). The remaining two seronegative subjects without Ad5-
specific CD8+ T-cell expansion had large baseline responses.   
 Four weeks after the first homologous Ad5 vector boost at week 4, 
Ad5-specific CD8+ T-cell frequencies were higher than baseline in both 
subject groups (p<0.03). Following this first boost, Ad5-specific CD8+ T-cell  
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Figure 21: Ad-specific CD8+ T-cells magnitude following vaccination. Five 
Ad5-seronegative (Ad5 nAb titer ≤18, gray boxes) and five Ad5-seropositive subjects (Ad5 
nAb titer >18, white boxes) received Merck Ad5 gag/pol/nef as described in Methods. CD8+ 
T-cell responses were measured by flow cytometry following whole Ad5 vector stimulation. 
Box plots represent 25th-75th percentile with lines being the 10-90% range. Outliers are shown 
as dots. Grey asterisk represent a significant increase from baseline in seronegative subjects 
and black asterisk represent a significant difference from baseline in seropositive subjects. 
Black bars represent a significant difference between the serogroups at that time point. A) 
Percentage of Ad5-specific CD8+ T-cells. Seronegative subjects were significantly increased 
above baseline at week 8 (p<0.03), 26 (p<0.03), 42 (p<0.001), 52 (p<0.01), and 78 
(p<0.001).  Total Ad-specific CD8+ T-cells were increased above baseline in seropositive 
subjects at week 4 (p<0.0001), 8 (p<0.03), 30 (p<0.02), and 42 (p<0.04). Serogroups 
significantly differed at week 42 (p<0.02), 52 (p<0.01), and 78 (p<0.003). B) Percentage of 
Ad5-specific Ki67+ CD8+ T-cells.  C) Percentage of Ki67+ total CD8+ T-cells. There was a 
significant increase above baseline in seronegative subjects at week 4 (p<0.01) and 
seropositive subjects at week 52 (p<0.12). 
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responses returned to pre-vaccination levels in baseline Ad5 seropositive 
subjects, and were only briefly expanded again at weeks 30 and 42 following 
the 2nd boost at week 26 (p<0.04). In contrast, Ad5-specific CD8+ T-cell 
responses remained elevated above baseline in the seronegative cohort 
(p<0.03). The only time we observed a difference in Ad5-specific CD8+ T-cell 
expansion between the seronegative and seropositive groups was following 
the third vaccination (weeks 42, 52 and 78; p<0.03)(Figure 21A). 
 The observed increase in Ad5-specific CD8+ T-cell frequencies was 
not reflected by an increase in Ki67 on Ad5-specific CD8+ T-cells after either 
the primary vaccination or subsequent boosts in either serogroup (Figure 
21B, p=N.S.). Furthermore, we detected only transient differences in global 
Ki67 levels on total CD8+ T-cells (Figure 21C). Thus, while increases in Ad5-
specific CD8+ T-cell frequencies were observed in both baseline Ad5-
seronegative and Ad5-seropositive subjects following vaccination, sustained 
changes or global effects on the proliferative capacity of CD8+ T-cells were 
not found.  
 
Vector-induced changes in Ad5-specific CD8+ T-cell functionality 
 At baseline, the majority of Ad5-specific CD8+ T-cells produced 
predominantly the effector functions MIP1α and perforin in both seropositive 
and seronegative subjects (Figure 22A). The percentage of Ad5-specific 
CD8+ T-cells producing TNFα was significantly higher in baseline seropositive 
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Figure 22: Ad5-specific CD8+ T-cell functionality following vaccination. . Five Ad5-
seronegative (Ad5 nAb titer ≤18, gray boxes) and five Ad5-seropositive subjects (Ad5 nAb 
titer >18, white boxes) received Merck Ad5 gag/pol/nef as described in Methods. CD8+ T-cell 
responses were measured by flow cytometry following whole Ad5 vector stimulation. Box 
plots represent 25th-75th percentile with lines being the 10-90% range. Outliers are shown as 
dots. Grey asterisk represent a significant increase from baseline in seronegative subjects 
and black asterisk represent a significant difference from baseline in seropositive subjects. 
Black bars represent a significant difference between the serogroups at that time point. A) 
Percent of the total Ad-specific response producing each cytokine. The total Ad-specific CD8+ 
response was computed by summing cells making at least IL-2, IFN-g, MIP1a, or TNFa as 
measured by flow cytometry. The percentage of the total Ad-specific response was then 
computed for each cytokine. The percentage of the total response consisting of TNFa was 
significantly higher in seropositive subjects (p<0.0005) at baseline. B) Percentage of IL-2+ Ad-
specific CD8+ T-cells. There was a significant increase above baseline in seronegative 
subjects at week 42 (p<0.01) and seropositive subjects at week 4(p=0.015). C) Percentage of 
TNFa+ Ad-specific CD8+ T-cells. There was a significant increase above baseline in 
seropositive subjects at week 52 (p<0.01) and 78 (p<0.02) and seropositive subjects at week 
4 (p<0.01). There was a significant difference at baseline in the percentage of TNFa+ CD8+ T-
cells between serogroups (p<0.05). D) Percentage of IFN-g Ad-specific CD8+ T-cells. The 
percentage of IFN-g+ CD8+T-cells was significantly increased above baseline in seronegative 
subjects at weeks 42 (p<0.004), 52 (p<0.003), and 78 (0.009) and in seropositive subjects at 
weeks (4 (p<0.0001), 8 (p<0.04), 30 (p<0.01) and 42 (p<0.04). There was a significant 
difference in the percentage of CD8+IFN-g+ CD8+ T-cells at week 78 between the serogroups 
(p<0.05). E) Percentage of MIP1a+ Ad-specific CD8+ T-cells. Seronegative subjects had a 
significantly increased percentage of MIP1a+ CD8+ T-cells above baseline at weeks 26 
(p<0.03), 42 (p<0.001), 52 (p<0.05) and 78 (p<0.004). Seropositive subjects had a 
significantly increased percentage of MIP1a+ CD8+ T-cells at week 4 (p<0.0005) compared 
with baseline There was a significant difference in the percentage of MIP1a+CD8+ T-cells 
between the serogroups at weeks 30 (p<0.04), 42 (p<0.012), 52 (p<0.005), and 78 (p<0.001). 
F) Percentage of perforin+ Ad-specific CD8+ T-cells. The percentage of perforin+CD8+ T-cells 
was significantly increased above baseline at weeks 26 (p<0.02), 42 (p<0.001) 52 (p<0.05) 
and 78 (p<0.004) in seronegative subjects and week 4 (p<0.0005) in seropositive subject. 
There was a significant difference in the percentage of MIP1a+CD8+ T-cells at weeks 30 
(p<0.04), 42 (p<0.012), 52 (p<0.005) and 78 (p<0.0013). 
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subjects prior to vaccination (p<0.001) but there were no differences between 
the groups for IL-2, IFN-γ, MIP1α or perforin.  
 Having observed increases in the total percentage of Ad5-specific 
CD8+ T-cells following vaccination we next determined whether vaccination 
affected the functionality of these cells. Consistent with the increase in Ad5-
specific CD8+ T-cell frequencies following the initial vector vaccination, 
baseline seropositive subjects showed a transient increase in the percentage 
of Ad5-specific CD8+ T-cells producing IL-2 (Figure 22B, p=0.015), TNFα 
(Figure 22C, p<0.01), and IFN-γ (Figure 22D, p<0.001) as well as the MIP1α 
(Figure 22E, p<0.0005), and perforin (Figure 22F, p< 0.0002). 
 The functionality of Ad5-specific CD8+ T-cells was similar in baseline 
seronegative and seropositive subjects, however in baseline seronegative 
subjects the expansion of Ad5-specific CD8+ T cells was delayed. Following 
the third vector dose baseline seronegative subjects had transiently elevated 
IL-2 producing CD8+ T-cells at week 42 (Figure 22B) and TNFα from weeks 
52-78 (Figure 22C).  CD8+ T cells that produced the effector functions IFN-γ, 
MIP1α and perforin were expanded for a more prolonged period of time 
(weeks 42-78) following the third vector dose.  This delayed expansion 
resulted in a higher percentage of Ad5-specific CD8+ T-cells in baseline 
seronegative subjects compared with baseline seropositive subjects following 
the third vector dose with MIP1α significantly elevated at weeks 30-78 and 
perforin at weeks 42-78.   
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Figure 23: Polyfunctional Ad5-specific CD8+ T-cell Responses. Five 
seronegative (Ad5 nAb titer ≤18) and five seropositive subjects (Ad5 nAb titer >18) received 
Merck Ad5 gag/pol/nef as described in Methods. CD8+ T-cell responses were measured by 
flow cytometry following whole Ad5 vector stimulation. A) Percentage of CD8+ T-cells 
expressing IFN-γand MIP1α. B) Percentage of Ad-specific CD8+ T-cells producing all five 
(red) functions: IL-2, MIP1α, TNFα, IFN-γ and Perforin, four (blue), three (green), two 
(orange), or one (yellow) of the five functions at each time point. Pies represent an average of 
the two groups. C) Bars represent the percentage of Ad-specific CD8+ T-cells making a 
combination of IL-2, TNFα, MIP1α, Perforin and IFN- γ at each week. Positive symbols 
represent cells staining positive for a function, and minus symbols represent cells staining 
negative for a function.  
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Although we observed increases in the frequencies of Ad5-specific CD8+ T-
cells producing various functions, the overall polyfunctionality of Ad5-specific 
CD8+ T-cells remained similar to baseline after vaccination (Figure 23A, B) in 
both groups. Furthermore, there was no substantial difference between the 
groups in the functional combinations produced (Figure 23C). In both groups 
the major response consisted of cells producing MIP1α with perforin and 
MIP1α with IFN-γ.  
.  
 
Ad5-specific CD8+ Phenotype 
 To investigate whether the effector-like functionality of Ad5-specific 
CD8+ T-cells corresponded to an effector phenotype, we assessed CD45RO 
and CD27 expression on Ad5-specific CD8+ T-cells. Ad5-specific cells that 
produced MIP1α, and perforin were primarily of an effector-like phenotype 
(CD27-CD45RO-) (Figure 24A), whereas more diverse memory subsets 
produced IFN-γ, TNFα, and IL-2. Approximately half of all Ad5-specific CD8+ 
T-cells had an effector-like phenotype at baseline in both seronegative and 
seropositive subjects (Figure 24B-C).  In baseline seropositive subjects, 
vaccination induced transient decreases in the percentage of Ad5-specific 
effector CD8+ T-cells (Figure 24C, p<0.05) that corresponded with an 
increase in the percentage of Ad5-specific effector memory cells (CD27-
CD45RO+; Figure 24D, p<0.05). In baseline seronegative subjects the 
effector phenotype observed at baseline remained stable following 
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vaccination with only a transient increase in the percentage of Ad5-specific 
memory cells observed at week 26 (Figure 24E). In the total CD8+ T-cell pool, 
the effector phenotype dominated in both serogroups at baseline. Following 
vaccination the percentage of total effector CD8+ T-cell  (Figure 24F) in 
seropositive subjects decreased, coinciding with an increase in total central 
memory-like CD8+ T-cells (CD27+CD45RO+; Figure 24H).  In seronegative 
subjects only transient changes in total CD8+ phenotype occurred (Figure 
24F-H).  Thus, while transient changes in memory phenotype were observed 
after vaccination, there were no sustained alterations in the memory 
phenotype of total or Ad5-specific CD8+ T-cells in either of the cohorts. These 
data suggest that Ad5-based vaccination does not induce global bystander 
CD8+ activation. 
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Figure 24: Phenotype of Ad5-specific CD8+ T-cells.  Five seronegative (Ad5 
nAb titer ≤18, gray boxes) and five seropositive subjects (Ad5 nAb titer >18, white boxes) 
received Merck Ad5 gag/pol/nef as described in Methods. Ad-specific CD8+ T-cell responses 
were measured by flow cytometry. Box plots represent 25th-75th percentile with lines being the 
10-90% range. Outliers are shown as dots. Grey asterisk represent a significant increase 
from baseline in seronegative subjects (p<0.05) and black asterisk represent a significant 
difference from baseline in seropositive subjects (p<0.05). Black bars represent a significant 
difference between the serogroups at that time point. A) The phenotype of Ad-specific CD8+ 
T-cells in a representative donor. Black areas represent total CD8+ T-cells and red dots 
represent Ad-specific CD8+ T-cells expressing IFN-γ, IL-2, MIP1α, Perforin or TNFα. B) 
Phenotype of Ad-specific CD8+ T-cells following vaccination. Black areas represent total 
CD8+ T-cells and red dots represent total Ad-specific CD8+ T-cells expressing IFN-γ, IL-2, 
MIP1α, Perforin or TNFα. C) Percentage of Ad-specific CD8+ T-cells with an effector 
phenotype (CD27-CD45RO-). D) Percentage of Ad-specific CD8+ T-cells with an effector 
memory phenotype (CD27-CD45RO+). E) Percentage of Ad-specific CD8+ T-cells with a 
central memory-like phenotype (CD27+CD45RO+). F) Percentage of total CD8+ T-cells with 
an effector phenotype (CD27-CD45RO-). G) Percentage of total CD8+ T-cells with an effector 
memory phenotype (CD27-CD45RO+). H) Percentage of total CD8+ T-cells with a central 
memory-like phenotype (CD27+CD45RO+). 
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Discussion 
 Recombinant Ad vectors are one of the primary vaccine platforms that 
are being tested for a wide range of human pathogens including HIV, malaria, 
and tuberculosis [171,173,174]. While these studies primarily focus on the 
generation of immune responses against the recombinant insert, an often-
overlooked issue is the induction of vector-specific immunity. Here we have 
examined Ad5-specific CD8+ T-cell responses in recipients of an Ad5 HIV-1 
vaccine candidate. We find that regardless of baseline Ad5 nAb serostatus, 
Ad5 vector administration results in a potent restimulation and expansion of 
pre-existing Ad5-specific CD8+ T-cells. This finding by itself is curious. One 
would have expected that E1-deleted Ad vectors only produce trace amounts 
of structural Ad proteins, as the transcription of late genes is under the control 
of a gene product of the deleted E1 domain. Nevertheless, as has been 
shown by others, CD8+ T cell responses to Ad vector particle proteins can be 
induced efficiently by cross priming. This mechanism would circumvent the 
need for de novo synthesis of Ad structural proteins for induction or recall of 
Ad-specific CD8+ T cells [175]. 
 At baseline, Ad5-specific CD8+ T-cells were detectable in 38 of 40 
subjects, despite a seroprevalence in the US of up to only 50%.  This 
magnitude of Ad5-reactive CD8+ T-cells is consistent with smaller studies 
showing Ad5-specific CD8+ T-cell responses in greater than 80% of subjects 
[59,82,121]. The prevalence of Ad5-specific CD8+ T-cells is likely the result of 
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cross-reactive CD8+ T-cells generated from infection with alternate serotypes. 
Many Ad proteins have highly conserved regions between various Ad 
serotypes, likely resulting in conservation of T-cell epitopes and the 
generation of cross-serotype reactive Ad5-specific CD8+ T-cells. Although we 
were able to observe a high frequency of responders after stimulation with an 
Ad5 vector in vitro, it is unclear whether detected responses were induced by 
a natural infection with an Ad5 virus. 
 Although vaccination increased frequencies of Ad5-specific effector 
CD8+ T-cells in both serogroups, there were no significant changes either 
within or between the groups for the cell cycle marker Ki67. Though the 
PBMC sampling in this study was intensive, there was a four-week period 
between vaccination and PBMC collection. It is possible that expansion of 
Ad5-specific T-cells and expression of Ki67 occurred transiently during this 
period. Alternatively, Ki67+ Ad5-specific CD8+ T-cells may have trafficked out 
of the peripheral blood by this time.   
 Interestingly, we observed no changes in polyfunctionality of Ad5-
specific CD8+ T-cells compared to baseline following vaccination in either 
serogroup. As we have previously observed (Chapter 3), Ad5-specific CD8+ 
T-cells are continuously maintained with both an effector-like phenotype and 
functionality. This likely reflects continued or intermittent exposure to Ad 
viruses from repeat infection with different serotypes or virus persistence. Ad5 
vector administration did not alter the baseline functional response, but 
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instead further expanded it. The expansion and high frequency of Ad-specific 
effector-like CD8+ T-cells could reduce the efficacy of Ad-vaccine boosting 
with both homologous and heterologous vector by direct lysis through perforin 
release of vector-transduced cells.   
 
Materials and Methods 
 
T-cell Responses 
Frozen peripheral blood mononuclear cells (PBMCs) were obtained 
from unvaccinated subjects at week 0 baseline (n = 25), seronegative 
subjects receiving three doses 3x1010 vp Mrk Ad5 gag/pol/nef at weeks 0, 4 
and 26 (n = 5, Ad5 neutralizing antibody titer ≤18) and seropositive (n = 5, 
Ad5 neutralizing antibody titer > 18) subjects receiving three doses 3x1010 vp 
Mrk Ad5 gag/pol/nef at weeks 0, 4 and 26 (n = five) as part of the Merck 
phase I 016 trial.  Ad5-specific T-cell responses were measured by 
stimulating PBMCs overnight with whole E1-deleted Ad5 vector. Cells were 
analyzed on a modified LSR II flow cytometer (BD Immunocytometry 
Systems). Data was analyzed using FlowJo 8.7.1 (TreeStar). Adenovirus 5 
neutralizing antibody titers were measured as previously described[163].  
 
Statistics 
 97
        Linear mixed effects models were performed to test for group differences 
over time as well as comparisons between baseline and subsequent time 
points within each group. Time was considered to be a discrete variable, 
lessening the power of these tests compared to tests where time is a 
continuous variable. Spearman correlations were used to test the relationship 
between Ad5 nAb titers and T-cell functions at baseline. Correlations over the 
entire time period were computed using partial correlation coefficients 
controlling for individual subject effects in the repeated measurements. All 
data was transformed using base e. Analyses was performed using SAS 9.1. 
 
Portions of this work have been submitted for publication: Hutnick NA, 
Carnathan DG, Dubey S, Cox K, Kierstead L, Makedonas G, Ratcliffe S, 
Robertson MR, Casimiro D, Ertl HC, Betts MR. “Vaccination with Ad5 vectors 
expands Ad5-specific CD8+ T cells without altering memory phenotype or 
functionality” In submission. 
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Chapter 6: Discussion 
 
Modern vaccinology has had one of the largest impacts on human 
health with the elimination of smallpox and 100% reduction in the occurrence 
of several devastating childhood diseases including polio, measles and 
pertussis in the United States. However, there are still areas of unmet need 
that result in the suffering and death of millions of people worldwide. Ad-
based vaccines are currently being researched as a means of inducing CD8+ 
CTL to prevent or modify infection. Though insert-specific responses are often 
analyzed, until recently, little work has been done to characterize Ad-specific 
immune responses. As highlighted by the STEP trial, it is important to 
understand vector-specific immunity to ensure a safe, efficacious vaccine. 
Here, we have presented the most thorough characterization of human Ad-
specific T-cell immunity following both natural infection and immunization. We 
find that Ad-specific T-cells are universally present in humans with an effector 
and effector memory like phenotype and functionality. Following Ad5-based 
vaccination both CD4+ and CD8+ Ad-specific T-cells transiently expanded, 
however, there were no durable changes in polyfunctionality, phenotype or 
homing marker expression. Ad5-seropositive and Ad5-seronegative subjects 
had similar baseline and post-vaccination Ad5-specific CD4+ T-cell 
responses, suggesting Ad5-specific CD4+ T-cells were not the cause of an 
increased risk of HIV infection in Ad5-seropositive STEP trial subjects.  
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Adenovirus Immunity from Natural Infection 
Ads have been developed as vectors for use in both gene therapy and 
vaccines. It is known that pre-existing Ad nAbs limit vaccine efficacy in 
humans, and animal studies suggest that CD8+ T-cells may also play a role. 
Seroprevalence has been used as a surrogate for pre-existing T-cell 
immunity, however, recent studies suggest that this may not be an accurate 
assumption.  Only 40% of US adults are seropositive to Ad5 yet studies have 
found T-cell responses to Ad5 to be almost universal [59,121]. To clarify Ad-
specific T-cell immunity we sought to further define the prevalence, 
functionality, phenotype and cross-reactivity of pre-existing Ad-specific T-cells 
in naturally infected humans.  
We studied Ad-specific T-cell responses in 17 healthy subjects by flow 
cytometry and found both CD4+ and CD8+ T-cell responses to replication- 
defective Ad5 vector in all subjects. This result is critical for vaccine design as 
seroprevalence cannot be used as a measure for pre-existing T-cell immunity. 
The universality of Ad5-specific T-cells despite a seroprevalence of only 40% 
suggests that Ad-specific T-cells are highly cross-reactive. To measure cross-
reactivity we stimulated PBMCs from the same 17 subjects with chimpanzee 
vectors (AdC) which have an exceptionally low seroprevalence in the United 
States [91]. One weakness of this study is the absence of nAb titers. Because 
PBMCs were obtained from aphaeresis, there was no plasma to determine 
nAb titers to Ad5, AdC6, and AdC7.  It is unlikely that subjects had been 
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exposed to AdC6 or AdC7, yet 16 of 17 subjects had both CD4+ and CD8+ T-
cells that responded to both AdC. Sequence homology within conserved 
regions of the major capsid protein, hexon, is over 90% between Ad5, AdC6 
and AdC7, and it is likely that T-cell epitopes are conserved between diverse 
Ad serotypes [176]. Indeed, we found that Ad reactive T-cells recognized 
epitopes within both the conserved and variable regions of Ad5, AdC6 and 
AdC7. The cross-reactivity of Ad-specific T-cells makes it difficult to define a 
truly Ad5-specific T-cell response.  
The cross-reactivity of Ad-specific T-cells may have important 
implications for Ad vector vaccines. To avoid the limitations of pre-existing 
immunity as measured by nAb, many researchers have developed vaccines 
based on rare serotypes with low seropositivity. However, these vectors will 
not avoid a reduction in vaccine efficacy by universally present Ad-specific 
CD8+ T-cells that may eliminate vector-transduced cells due to an at least 
90% homology between human serotypes. Likewise, using heterologous 
vectors in a prime boost schedule will also not avoid pre-existing Ad-reactive 
T-cells. The impact on efficacy from pre-existing Ad-specific CTLs in humans 
is not known, but based on the universality of Ad-reactive T-cells it will be a 
hurtle that needs to be overcome by all serotype vectors in order for an Ad-
based vaccine to succeed in the clinic.   
The cross reactivity of Ad-specific T-cells also suggests they may be 
continually restimulated when an individual is infected with any of the 52 
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serotypes throughout their life. In addition to constant restimulation by repeat 
infection, Ad has been shown to persist in the lymphatic tissue and could 
produce continual antigen presentation and T-cell stimulation [59,71]. 
Indeed we found that Ad-reactive T-cells display an effector and effector 
memory-like phenotype and produce predominantly effector functions such as 
MIP1α and perforin.  The effector functionality of Ad-specific CTL may make 
them efficient at eliminating vector-infected cells and reducing vaccine 
efficacy compared with other viral platforms. 
The effector-like characteristics of Ad-specific T-cells appears to be 
functionally unique, even among other human viruses. A recent study 
accessed the functionality of virus specific CD8+ T-cells to Epstein-Barr virus 
(EBV), cytomegalovirus (CMV), Ad, and influenza (Flu) [166]. Both CMV and 
EBV establish latency whereas Flu is an acute infection. Approximately 75% 
of Ad-specific CD8+ T-cells expressed perforin whereas only 25% of CMV -
specific and less than 5% of EBV- and Flu-specific CD8+ T-cells expressed 
perforin [166].  In contrast to the results for perforin, IL-2 production was high 
in EBV- and Flu-specific CD8+ T-cells, low in CMV-specific CD8+ T-cells and 
virtually undetectable in Ad-specific CD8+ T-cells. Perforin positive CD8+ T-
cells had a higher level of the T-cell transcription factor, T-bet. A large portion 
of Ad-specific T-cells express perforin, therefore it is possible Ad-specific T-
cell also express a high level of T-bet. However, the transcriptional profile of 
human Ad-specific T-cells has yet to be assessed.  
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Though Ad infection is considered acute clinically, the continual 
presentation of antigen may make it immunologically more similar to a chronic 
non-latent infection such as HIV or HCV. One hallmark of chronic infection is 
the eventual exhaustion of T-cells from continual antigen stimulation. T-cell 
exhaustion can be measured by the expression of surface inhibitory receptors 
such as PD-1, CTLA-4 and Lag3 [152]. Exhausted T-cells undergo a 
hierarchical loss of functions such as IL-2 and TNFα  with IFN-γ being the last 
function lost [177,178]. The effector-like functionality with perforin and MIP1α 
production in our cohort is not consistent with an exhausted phenotype.  We 
also observed Ad-specific CD4+ and CD8+ T-cells were capable of 
proliferating upon restimulation. Following the 5-day Ad stimulation CFSE low 
cells that had undergone proliferation had a central memory-like 
CD27+CD45RO+ phenotype. Together, these data suggest that although Ad 
antigens may be continually present, it does not appear that Ad-specific T-
cells undergo functional exhaustion. However, the expression of surface 
receptors associated with exhaustion has not been performed. 
 
Effect of Ad vector vaccination on Ad-specific CD4+ T-cells 
 The Merck Ad5 HIV-1 vaccine trial showed a possible increased risk of 
infection in baseline Ad5-seropositive subjects. One hypothesis to explain this 
result was Ad5-seropositive subjects would have higher levels of baseline 
Ad5-specific CD4+ memory T-cells. Upon vaccination, these cells would 
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become activated, proliferate, and up regulate expression of the HIV-1 entry 
co-receptor CCR5. It is also proposed that activated Ad5-specific memory 
CD4+ T-cells may traffic to the initial site of Ad infection in mucosal tissues 
such as the gut, which is also a preliminary site for HIV-1 replication. 
Therefore, vaccinating an Ad5-seropositive subject would result in the 
enrichment of CD4+ T-cells that are optimal targets for HIV-1 infection. 
Our study of Ad5-specific CD4+ T-cells in subjects from the phase I 
STEP precursor study indicates that the pre-existing Ad5-specific CD4+ T-cell 
hypothesis does not explain the STEP trial results. First, prior to vaccination 
Ad5-seropositive and Ad5-seronegative subjects had similar levels of Ad5-
specific CD4+ T-cells. Therefore, pre-existing CD4+ T-cells were not present 
in Ad5-seropositive subjects only. Similar results were observed by other 
groups [121,179,180] with only one study suggesting a correlation between 
Ad-specific T-cell responses and Ad5 nAb [181]. Second, following 
vaccination, Ad5-specific CD4+ T-cells were transiently expanded to an equal 
degree in both Ad5-seropositive and Ad5-seronegative subjects. This 
suggests Ad5-seropositive subjects do not generate more Ad5-specific CD4+ 
T-cell following vaccination. Additionally, the expansion in both groups was 
only transient and the increased infection rate in Ad5-seropositive subjects 
occurred up to 52 weeks following vaccination.  
In addition to there being no difference in the presence or expansion of 
Ad5-specific CD4+ T-cells between Ad5-seronegative and Ad5-seropositive 
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subjects, we also saw no increase or difference between serogroups in the 
activation of Ad5-specific CD4+ T-cells as measured by Ki67. One 
shortcoming of our study was not measuring the expression level of CCR5 on 
Ad5-specific CD4+ T-cells.  Whether activated Ad5-specific CD4+ T-cells 
express more CCR5 and are more susceptible to HIV-1 infection has recently 
been debated. In STEP study participants there was no difference in the level 
of CCR5 expression in HIV-1 infected cases and non-cases [82]. Also, the 
level of CCR5 expression in other studies was found to be similar between 
baseline Ad5-seropositive and Ad5-seronegative subjects and did not 
increase with vaccination [121,182]. However, two opposing studies suggest 
that culturing Ad5-specific CD4+ T-cells with Ad5 vector-infected dendritic 
cells resulted in proliferation, CCR5 upregulation, and increased HIV-1 
infection [181,183]. It is possible the differences in results between the 
various studies were due to the use of a short-term versus long-term 
stimulation of PBMCs. We are planning on further studying the effect of the 
two stimulation assays on activation and homing marker expression.  
One caveat to our findings is that all responses were measured only in 
T-cells from the blood. It is hypothesized that Ad5-specific CD4+ memory T-
cells may traffic to the gut mucosal upon activation by vaccination. Currently, 
there have been no reported gut biopsies performed on Ad5 vaccinated 
humans however studies are planned by the HIV vaccine trials network 
(HVTN). As a surrogate for measuring the magnitude and phenotype of Ad5 
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specific CD4+ T cells in the gut mucosa, we measured the expression of gut 
homing markers on Ad5-specific peripheral blood T-cells. The α4β7 integrin 
heterodimer is expressed on T-cells and binds to MAdCAM-1 on venule 
epithelial cells allowing T-cells to migrate into gut mucosal tissue. The α4β7 
heterodimer may also be a co-receptor for HIV-1 entry, therefore an increase 
in heterodimer receptor expression on Ad5-specific CD4+ T-cells could also 
make them more susceptible to HIV-1 infection [184,185]. It is unlikely this 
hypothesis is correct as T-cells appear to down regular α4β7 upon entering gut 
mucosal tissue. Preliminary data of gut biopsies from non-vaccinated humans 
shows little total or Ad5-specific α4β7 expression on CD4+ T-cells. 
We observed no increase in the expression of the mucosal homing 
integrins α4 and β7 on peripheral blood CD4+ T-cells following vaccination in 
either serogroup. However, recent studies have seen contradictory results 
[181,183]. The study by Benlahrech et al. found that memory CD4+ T-cells 
from Ad5-seropositive subjects cultured for 5 days with Ad5 pulsed dendritic 
cells proliferated and upregulated the expression of CCR5 and α4β7. The 
stimulation method used and functionality results differed from our study and 
may account for the differences in α4β7 expression observed.  There were 
also a number of caveats that may impact the interpretation of data. First, the 
study only included normal subjects and did not examine whether post 
vaccination responses differed from baseline or were altered in baseline Ad5-
seronegative subjects after the first dose when they became Ad5-
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seropositive. Second, T-cells stimulated with tetanus toxoid as a control had a 
similar level of proliferation and α4β7 upregulation as Ad5 stimulated CD4+ T-
cells. The correlation for tetanus toxoid-specific CD4+ T-cell responses and 
tetanus toxoid nAb titer was not shown and would be a more appropriate 
control to determine if Ad5-specific CD4+ T-cell responses are unique in Ad5- 
seropositive subjects or if the responses observed are simply a characteristic 
of a virus-specific memory T-cell response. 
The study by Chakupurakal et al. also saw an increase in α4β7 when 
CD4+ T-cell were cultured with replication defective E1- and E3- deleted Ad5 
vector for 7 days. The group observed an approximately 40% increase in the 
percentage of CD4+ α4β7+ T-cells compared with our results. This is likely a 
result of the extended in vitro assay but could also suggest a large degree of 
variability in study populations, or a difference in cytometry procedures. We 
have plans to perform a similar assay on Merck phase I vaccinated subjects 
to determine how α4β7 differs in a 6 hour Ad stimulation compared with a 6 
day stimulation and the effect vaccination has on α4β7 expression. 
T-cell trafficking in humans is not well understood but is important for 
the field of vaccinology. We measured gut mucosal homing markers in the 
blood as a surrogate for the gut population of Ad5-specific CD4+ T-cells. 
However, the origin and fate of Ad-specific CD4+ T-cells in the blood is 
unclear. 90% of all CD4+ T-cells reside in the gut mucosa. It is unclear 
whether cells in the blood expressing gut homing markers are recently 
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activated naïve cells trafficking to the mucosa where they will stay, or whether 
effector and memory cells in the mucosa can traffic between the gut and the 
blood. Another question is what induce a naïve cell to express α4β7 and traffic 
into the gut, and does stimulating naïve Ad-specific CD4+ T-cells result in the 
same homing patterns as stimulating effector or memory Ad-specific CD4+ T-
cells? Being able to manipulate the homing properties of antigen specific T-
cells would increase the efficacy of vaccines designed to prevent mucosal 
infections such as HIV. Studying T-cell responses to replicating Ad infection in 
animal models may help us to better understand what shapes the natural T-
cell response to Ad and how Ad-based vaccines alter this immunity.  
 It has been two years since the STEP trial was halted and the debate 
over whether Ad5 vaccination increased the risk of HIV-1 infection in Ad5-
seropositive subjects continues. Our results suggest that Ad5-specific CD4+ 
T-cells were not the cause of an increased risk. However, it is possible that 
there are differences in the magnitude or activation of Ad5-specific CD4+ T-
cells in the mucosal tissue of Ad5-seropositive vs. Ad5-seronegative subjects 
that were not observed in the blood. Indeed, Ad-specific CD4+ T-cells have 
been readily detected in the gut mucosal tissue of healthy adults [59].  
 Another limitation of our study is the timeline of subject sampling. One 
weakness of analyzing STEP trial samples was the absence of baseline 
PBMCs collected prior to vaccination. Though our study consisted of 
extensive sampling every four weeks after vaccination as well as long-term 
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follow-up, it is possible that Ad5-reactive CD4+ T-cells were activated or 
expanded in seropositive subjects following vaccination but this was not 
observed by 4 weeks after vaccination. For example, Ki67 is expressed when 
a cell enters the cell cycle but not when a cell is in a resting state [186]. 
Another possibility is that there was an increase in activated cells, but by 4 
weeks after vaccination they had contracted to baseline levels or left the 
blood to enter the lymphatic system or peripheral tissues. Following 
vaccination with the yellow fever 17D virus or vaccinia virus, the magnitude of 
activated (Ki67+, Bcl-2low; CD38+, HLA-DR+) CD8+ T-cells peaked at day 15 
and had returned to baseline by day 30 [187]. 
 One debate in the area of HIV vaccines is what is the best animal 
model to replicate human infection. The same question needs to be asked for 
Ad vaccine candidates. Pre-exposing mice or monkeys to a replication- 
defective Ad vector does not mimic pre-existing immunity to natural infection 
in humans where there is repeat exposure to multiple Ad serotypes over the 
lifetime of an individual and persistence in lymphatic tissue. Simian Ad have 
been identified, and Rhesus macaques infected with replication competent 
simian Ad may provide an effective model for human pre-existing immunity 
[188]. However, the persistence of Rhesus Ad will need to be studied as well 
as the phenotype and functionality of the T-cell response. If the natural Ad-
specific T-cell response resembles humans, Rhesus macaques infected with 
Rhesus Ad may provide a good model to study T-cell activation and trafficking 
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following Ad vaccination and Ad vaccine efficacy. An accurate animal model 
may also clarify the debate about whether Ad-specific CD4+ T-cells were 
responsible for the increased susceptibility observed in the STEP trial. 
 
Effect of Vaccination on Ad-specific CTL 
 Both Ad-specific nAb and CTL may limit vaccine efficacy by reducing 
vector-transduced cells before the insert gene is expressed. We found that 
Ad5-specific CD8+ T-cells were detectable at baseline in 38 of 40 subjects 
despite an Ad5 seroprevalence of only 40% in the US. This CD8+ T-cell 
prevalence is similar to that detected for Ad5-specific CD4+ T-cells, and is 
likely due to cross-reactivity between multiple serotypes. Also similar to Ad5-
specific CD4+ T-cells, Ad5-specific CD8+ T-cells were effector-like even at 
baseline. Periodic restimulation by infection with multiple serotypes may be 
the reason why Ad5-specific CD8+ T-cells are maintained in an effector state.  
 Vector induced expansion of Ad5-specific CD8+ T-cells occurred 
following the first vaccine dose in Ad5-seropositive subjects and the third 
vaccine dose in Ad5-seronegative subjects. The reason behind this 
differential CD8+ T-cell expansion between the serogroups is unclear, but 
may have been caused by Ad5-specific nAb. Ad5 nAb levels increased in 
baseline Ad5-seronegative and Ad5-seropositive subjects following 
vaccination but remained higher in Ad5-seropositive subjects throughout the 
study. Ad5 nAb binding to vector could facilitate vector uptake by antigen-
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presenting cells, cross presentation and expansion of Ad-specific CD8+ T 
cells [189]. Alternatively, late responses in Ad5-seropositive subjects could 
have been dampened by high nAb titers binding to vector and preventing 
infection, thereby reducing the effective vector dose and CD8+ T-cell 
response.  
The high percentage of perforin expressing Ad5-specific effector CD8+ 
T-cells should efficiently eliminate vector-transduced cells as perforin 
expressing CD8+ T-cells have been shown to effectively lyse target cells 
[190]. Studies in mice have shown transgene expression decreases by 98%  
20 days after vaccination in immune competent mice but persists for over 110 
days at post-vaccination levels in immune compromised nude mice. This data 
suggests the reduction in transgene expression is likely due to immune 
destruction of transduced cells [191]. The destruction of transduced cells and 
limited insert expression may result in the need for booster vaccinations to 
maintain effective lifelong immunity. 
 Repeat homologous vaccination resulted in the expansion of Ad-
specific CD8+ T-cells in both Ad5-serogroups, however, we observed no 
changes in the polyfunctionality of Ad5-specific CD8+ T-cells compared to 
baseline in either serogroup. This is a classic example of original antigenic 
sin, where the quality of the response induced by the primary antigen 
exposure is not altered by subsequent antigen exposure, even if the antigen 
is slightly altered as may occur by infection with a heterologous serotype. Our 
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findings have important implication for the field of therapeutic vaccination. The 
goal of a therapeutic vaccine is to boost anti-viral immunity after infection to 
control viremia and disease progression. Though therapeutic vaccines for HIV 
have succeeded in boosting anti-HIV CD8+ T-cell responses, they have been 
ineffective at controlling viremia [192]. Without therapy, HIV-specific CD8+ T-
cell responses are unable to control and clear the virus following natural 
infection. Our data suggests the ineffective naturally induced HIV-specific 
CD8+ response would be expanded by therapeutic vaccination with HIV 
antigens but the ineffective functionality would not be altered. In order for 
therapeutic vaccination to be effective, we need to understand what an 
effective HIV-specific CD8+ T-cell response is and how we can modify the 
naturally induced response to one that is capable of controlling or clearing 
virus. Unpublished work from our lab suggests a CD8+ HIV-specific response 
with the ability to upregulate perforin may be protective. Further work is being 
performed to identify transcription factors associated with perforin production 
and may provide insights into how the immune system could be manipulated 
to produce and effective anti-HIV CD8+ T-cell response.  
Future directions  
 This work was initiated as part of a larger project to develop rare 
serotype Ad vaccines to prevent HIV infection. By studying human Ad-specific 
T-cell responses this work has provided some important insights and 
 112
questions about the efficacy and outcome of Ad vaccines. Our results have 
also raise some critical questions for further research. 
 By studying Ad-specific T-cell immunity to human and chimpanzee 
serotypes we confirmed that Ad-specific T-cells are highly pervasive and 
cross-reactive. One limitation of our study is the assumption that subjects 
were seronegative to the chimpanzee vectors based on studies showing low 
seropositivity in healthy US adults. To truly demonstrate cross-reactivity future 
studies will perform the same studies outlined in Chapter 3 using subjects 
from South Africa, Uganda and Botswana. Serum from these subjects will be 
available so the nAb titer to AdC6, AdC7 and Ad5 can be measured in 
addition to T-cell responses.  
 Studying Ad-specific immunity in African subjects will also help to 
define the utility of rare serotype vaccines. Though an Ad serotype may be 
rare in developed nations, prevalence is often high in third world countries 
where water, sewage, and sanitation systems are not as consistent, allowing 
for the spread of Ad. There have been few studies demonstrating pre-existing 
T-cells to rare Ad serotypes. Future studies will be examining the T-cell 
response and nAb levels to one rare human serotype in development, Ad26, 
in both US and African subjects [193]. Preliminary results suggest the 
magnitude and prevalence of Ad26-reactive T-cells is similar to Ad5-reactive 
T-cell in the US.  This study will help define the utility of Ad26 as a vector 
compared with the extensively tested Ad5.  
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Another important question is whether vector-specific T-cell responses 
influence insert-specific response. The effector-like qualities of Ad-specific 
CD8+ T-cells would be desirable as insert-specific responses for a T-cell 
vaccine. CMV infection is similar to Ad as both viruses persist and are known 
to induce potent effector responses in humans [166]. Recent work has shown 
induction of effector memory cells and protection from SIV infection in CMV 
vaccinated monkeys [194], however the risks for a CMV vector are higher 
than other viral vectors, limiting their clinical development. Therefore, being 
able to induce effector like immunity through adjuvants and cytokines to alter 
the functionality of T-cell responses in other viral vectors may be critical to the 
development of an effective CTL vaccine.  
Future studies are also planned to examine the transcriptional profile of 
Ad-specific CD8+ T-cells. By understanding the molecular mechanism behind 
effector CTL development and perforin production we may be better prepared 
to design successful vaccines capable of eliciting insert specific CTL. Studies 
in our lab suggest the transcription factor T-bet is expressed at a higher level 
in perforin producing CTL. By understanding what induces T-bet expression 
we may be able to increase perforin production in activated T-cells and viral 
elimination.  
Large Ad specific effector CD8+ T-cell responses may alternatively 
result in a diminished CD8+ T-cell response to the insert. The average 
response to HIV insert proteins in the STEP trial was 0.4-1.0% whereas the 
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average response to Ad in our studies following vaccination was 2.7% and as 
high as 8% [180]. There are a number of reasons why this may occur. The 
response to Ad may be larger because Ad transfected cells are eliminated 
before the insert is expressed, cells are transduced and survive but 
expression of the insert is low, or Ad epitopes more efficiently bind MHC class 
I, thereby skewing the immune response towards Ad. A possible strategy for 
reducing Ad vector immunity would be to delete more of the vector genome to 
reduce wild type Ad gene expression. Another method would be to improve 
the efficacy of transgene expression so a lower dose of Ad-vector could be 
delivered, thereby reducing Ad capsid protein levels. 
To address whether insert-specific responses positively or negatively 
correlate with vector-specific responses, we plan on comparing the phenotype 
and functionality of Ad-specific and HIV-specific T-cell responses in Merck 
phase 1 016 trial participants.  We have obtained PBMCs from over 50 
subjects with a range of Ad5 nAb titers allowing for the comparison of how 
nAbs and Ad-specific CD8+ T-cells may affect insert specific responses. This 
would be a novel study in humans as vector- specific immunity including nAbs 
and T-cells before and after vaccination has not be extensively studied.  
In addition to increasing efficacy of Ad-based vaccines, a major 
concern following the STEP trial is whether Ad-based vaccines can be safely 
used in high-risk HIV populations. To further address whether Ad-specific T-
cells may have been responsible for the increased risk of infection observed 
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in Ad5-seropositive STEP trial participants we are planning an extensive 
analysis of phase I Merck Ad5 trial participants. In addition to examining α4β7 
expression, future studies will measure the gut associated homing receptors 
CD161, and CCR10 to better define the trafficking and phenotype of Ad-
specific CD4+ T-cells before and after Ad5 vaccination.  
This thesis comprises the largest body of work to date studying human 
Ad-specific T-cell responses following natural infection and vaccination. I 
have shown that Ad-specific T-cells are prevalent, effector-like, and cross-
reactive. Vaccination only transiently expanded Ad-specific T-cells 
irrespective of Ad5-serostatus and was unlikely to have been the cause of the 
increased risk of HIV infection in seropositive STEP trial participants. These 
studies have provided us with a good understanding of Ad-specific T-cell 
responses, as well as highlighted areas of further study where we may be 
able to improve Ad-based vaccine efficacy and safety.  
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Table 4: Ad5 hexon peptide pools. 
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Table 5: AdC6 Hexon Peptide Pools. 
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Table6: AdC7 hexon peptide pools. 
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